Original Article
Circulating Angiogenic Factors and the Risk of Preeclampsia
N Engl J Med 2004; 350:672-683February 12, 2004
- Abstract
Background
The cause of preeclampsia remains unclear. Limited data suggest that excess circulating soluble fms-like tyrosine kinase 1 (sFlt-1), which binds placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), may have a pathogenic role.
Methods
We performed a nested case–control study within the Calcium for Preeclampsia Prevention trial, which involved healthy nulliparous women. Each woman with preeclampsia was matched to one normotensive control. A total of 120 pairs of women were randomly chosen. Serum concentrations of angiogenic factors (total sFlt-1, free PlGF, and free VEGF) were measured throughout pregnancy; there were a total of 655 serum specimens. The data were analyzed cross-sectionally within intervals of gestational age and according to the time before the onset of preeclampsia.
Results
During the last two months of pregnancy in the normotensive controls, the level of sFlt-1 increased and the level of PlGF decreased. These changes occurred earlier and were more pronounced in the women in whom preeclampsia later developed. The sFlt-1 level increased beginning approximately five weeks before the onset of preeclampsia. At the onset of clinical disease, the mean serum level in the women with preeclampsia was 4382 pg per milliliter, as compared with 1643 pg per milliliter in controls with fetuses of similar gestational age (P<0.001). The PlGF levels were significantly lower in the women who later had preeclampsia than in the controls beginning at 13 to 16 weeks of gestation (mean, 90 pg per milliliter vs. 142 pg per milliliter, P=0.01), with the greatest difference occurring during the weeks before the onset of preeclampsia, coincident with the increase in the sFlt-1 level. Alterations in the levels of sFlt-1 and free PlGF were greater in women with an earlier onset of preeclampsia and in women in whom preeclampsia was associated with a small-for-gestational-age infant.
Conclusions
Increased levels of sFlt-1 and reduced levels of PlGF predict the subsequent development of preeclampsia.
Media in This Article
Figure 1
Concentrations of Soluble fms-like Tyrosine Kinase 1 (sFlt-1).Figure 2
Concentrations of Placental Growth Factor (PlGF).Article Activity
- Article
Preeclampsia affects about 5 percent of pregnancies, resulting in substantial maternal and neonatal morbidity and mortality.1,2 Although the cause remains unclear, the syndrome may be initiated by placental factors that enter the maternal circulation and cause endothelial dysfunction resulting in hypertension and proteinuria.3-6
We and others have recently shown that soluble fms-like tyrosine kinase 1 (sFlt-1), a circulating antiangiogenic protein, is increased in the placenta5,7 and serum5,8,9 of women with preeclampsia. This protein acts by adhering to the receptor-binding domains of placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), preventing their interaction with endothelial receptors on the cell surface and thereby inducing endothelial dysfunction. Decreased concentrations of circulating free PlGF and free VEGF have been noted during clinical preeclampsia5 and even before its onset.10,11 We have recently demonstrated that exogenous sFlt-1 administered to pregnant rats induces hypertension, proteinuria, and glomerular endotheliosis.5 Moreover, a 50 percent reduction in VEGF production in renal podocytes in mice with podocyte-specific heterozygosity for VEGF resulted in glomerular endotheliosis and massive proteinuria.12 Hypertension and proteinuria have been reported in patients with cancer who were treated with VEGF-signaling inhibitors.13,14 Taken together, these observations suggest that excess sFlt-1 may have a pathogenic role in preeclampsia.5
In order to describe the gestational patterns of circulating sFlt-1, free PlGF, and free VEGF in normotensive and preeclamptic pregnancy, we performed a nested case–control study within the Calcium for Preeclampsia Prevention (CPEP) trial, using archived serum samples obtained before labor. Concentrations were analyzed in a cross-sectional fashion within intervals of gestational age and according to the time before the onset of preeclampsia. We hypothesized that the sFlt-1 level would be elevated before the onset of clinical disease, with reciprocal decreases in the levels of free PlGF and VEGF.
Methods
Participants and Specimens
The CPEP trial was a randomized, double-blind clinical trial conducted from 1992 to 1995 to evaluate the effects of daily supplementation with calcium or placebo on the incidence and severity of preeclampsia.15,16 Healthy nulliparous women with singleton pregnancies were enrolled between 13 and 21 weeks of gestation at five participating U.S. medical centers and were followed until 24 hours after delivery, with the use of a common protocol and identical data-collection forms. Written informed consent was obtained from all the participants. Gestational age was determined by means of ultrasonographic examination. Serum specimens were requested from women before enrollment in the trial, at 26 to 29 weeks of gestation, at 36 weeks if they were still pregnant, and when hypertension or proteinuria was noted. “End-point specimens” were obtained at or after the onset of signs of preeclampsia but before labor and delivery.15,16
For the present study, we selected women with complete outcome information, serum samples obtained at less than 22 weeks of gestation, and a live-born male infant. This group had previously been selected for a study of fetal DNA and preeclampsia, in which fetal and maternal DNA were differentiated through the amplification of a gene on the Y chromosome. Analysis of previous work5 revealed no significant differences in the sFlt-1 or PlGF concentrations between 10 women with preeclampsia who delivered a male infant and 8 women with preeclampsia who delivered a female infant (sFlt-1 concentration, 6120 pg per milliliter vs. 5404 pg per milliliter; P=0.78; PlGF concentration, 99 pg per milliliter vs. 125 pg per milliliter; P=0.42).
Of the 4589 women enrolled in the CPEP trial, we excluded 253 who were lost to follow-up, 21 whose pregnancy ended before 20 weeks, 13 who had missing data on maternal or perinatal outcome, 4 who had no data on smoking history, 9 in whom the presence of hypertension had not been verified by the team that reviewed each chart, and 32 who had a stillbirth, leaving 4257 women. Of these women, 2156 had a male infant. After the exclusion of 1 woman whose infant had a chromosomal abnormality, 381 women with gestational hypertension, and 43 without a base-line serum specimen, 1731 women remained. Preeclampsia developed in 175 of these women, whereas 1556 remained normotensive throughout pregnancy.
Calcium supplementation did not affect the serum concentrations of angiogenic factors. Specimens collected at 8 to 20 weeks of gestation were considered the base-line specimens and were obtained before the administration of calcium or placebo. At 21 to 32 weeks, the mean serum sFlt-1 level in the controls who were given placebo was 866 pg per milliliter, as compared with 889 pg per milliliter in the controls who were given calcium supplements (P=0.57); the mean PlGF level was 765 pg per milliliter and 746 pg per milliliter, respectively (P=0.78); and the mean VEGF level was 13.0 pg per milliliter and 12.5 pg per milliliter, respectively (P=0.80). At 33 to 41 weeks, the concentrations of these factors also did not differ significantly between these two groups.
Since calcium supplementation had no effect on the risk or severity of preeclampsia16 or on the concentrations of angiogenic factors, the women with preeclampsia and the controls were chosen without regard to whether they had received calcium supplementation or placebo. For each woman with preeclampsia, one normotensive control was selected, matched according to enrollment site, gestational age of the fetus at the collection of the first serum specimen (within 1 week), and storage time of the samples at –70°C (within 12 months). A total of 120 of 159 matched pairs were randomly chosen for the analysis of all 655 serum specimens that were obtained before labor. Of the 240 women included in the study, 21 (8.8 percent) contributed one serum specimen, 52 (21.7 percent) contributed two specimens, 139 (57.9 percent) contributed three, 27 (11.2 percent) contributed four, and 1 (0.4 percent) contributed five. The mean gestational age of the fetus at the collection of the first serum specimen was 112.8 days among the women with preeclampsia and 113.6 days among the controls; the mean duration of freezer storage was 9.35 years and 9.39 years, respectively. Since most women had three or fewer serum specimens, we analyzed the data largely in a cross-sectional manner. Among the few women with more than one specimen per period, the earliest specimen was selected for analysis.
Preeclampsia was defined as a diastolic blood pressure of at least 90 mm Hg and proteinuria of at least 1+ (30 mg per deciliter) on dipstick testing, each on two occasions 4 to 168 hours apart. Severe preeclampsia was defined as the HELLP syndrome (hemolysis, elevated liver-enzyme levels, and a low platelet count), eclampsia, or preeclampsia with either severe hypertension (diastolic blood pressure ≥110 mm Hg) or severe proteinuria (urinary protein excretion ≥3.5 g per 24 hours or findings of ≥3+ [300 mg per deciliter] on dipstick testing). Detailed definitions have been published previously.15,16 The time of onset of preeclampsia (the end point) was defined as the time of the first elevated blood-pressure or urinary protein measurement leading to the diagnosis of preeclampsia. A small-for-gestational-age infant was defined as an infant whose birth weight was below the 10th percentile according to U.S. tables of birth weight for gestational age that accounted for race, parity, and the sex of the infant.17 Because the study used data and specimens that were collected as part of the CPEP trial and could not be linked to identifiable women, the Office of Human Subjects Research of the National Institutes of Health granted it an exemption from the requirement for review and approval by the institutional review board.
Procedures
Assays were performed by personnel who were unaware of the outcome of the pregnancy. Specimens were randomly ordered for analysis. Enzyme-linked immunosorbent assays (ELISAs) for human sFlt-1 (also called soluble VEGF receptor 1), free PlGF, and free VEGF were performed in duplicate, as previously described, with the use of commercial kits (R&D Systems).5 The minimal detectable doses in the assays for sFlt-1, PlGF, and VEGF were 5, 7, and 5 pg per milliliter, respectively, with interassay and intra-assay coefficients of variation of 7.6 and 3.3 percent, respectively, for sFlt-1; 10.9 and 5.6 percent, respectively, for PlGF; and 7.3 and 5.4 percent, respectively, for VEGF.
Statistical Analysis
Chi-square tests were used for the comparison of categorical variables, and t-tests were used for the comparison of continuous variables. Although the arithmetic mean concentrations are reported in the text and figures, statistical testing was conducted after logarithmic transformation. All P values are two-tailed. The Wilcoxon rank-sum test was also applied to the comparisons within the gestational-age intervals and provided P values indicating similar significance. Odds ratios were adjusted with the use of logistic-regression analysis.
Results
Characteristics of the Women
Of the 120 women with preeclampsia, 80 had mild preeclampsia and 40 had severe preeclampsia, including 3 with the HELLP syndrome and 3 with eclampsia. As compared with the controls, the women with preeclampsia had greater body-mass index (the weight in kilograms divided by the square of the height in meters) and higher blood pressure at the time of enrollment in the CPEP trial; a larger proportion of their current pregnancies were complicated by preterm delivery or resulted in small-for-gestational-age infants (Table 1Table 1
Characteristics of Women Who Later Had Preeclampsia and Controls at Enrollment in the CPEP Trial and Characteristics of Their Infants.).Differences in sFlt-1, PlGF, and VEGF Levels
We first confirmed that the serum levels of sFlt-1, free PlGF, and free VEGF were altered in women with clinical preeclampsia.5,8 Among 23 pairs of women with preeclampsia and controls with fetuses of similar gestational age, specimens drawn after the onset of preeclampsia (“end-point specimens”) had higher levels of sFlt-1 and lower levels of PlGF and VEGF than specimens from controls (mean sFlt-1 level, 4382 pg per milliliter vs. 1643 pg per milliliter; P<0.001; mean PlGF level, 137 pg per milliliter vs. 669 pg per milliliter; P<0.001; and mean VEGF level, 6.4 pg per milliliter vs. 13.9 pg per milliliter; P=0.07).
Gestational Changes in the sFlt-1 Level
To evaluate gestational patterns, we performed a cross-sectional analysis of serum obtained within gestational-age intervals of four to five weeks (Figure 1AFigure 1
Concentrations of Soluble fms-like Tyrosine Kinase 1 (sFlt-1).). The sFlt-1 concentrations in controls remained constant until 33 to 36 weeks of gestation, when they increased by approximately 145 pg per milliliter per week until labor and delivery. In the women in whom preeclampsia later developed, but before the onset of preeclampsia, the concentrations began to increase at 21 to 24 weeks of gestation, with a steeper increase at 29 to 32 weeks. When we compared the sFlt-1 concentrations at different stages of pregnancy in specimens from women in whom preeclampsia developed, we found that among women with specimens drawn when their fetuses were in the same gestational-age interval, those who already had clinical preeclampsia had significantly higher concentrations than those who did not.The concentrations of sFlt-1 were increased in women who later had preeclampsia beginning 11 to 9 weeks before the onset of preeclampsia (Figure 1B). Samples drawn within five weeks before the onset of preeclampsia revealed a more rapid increase in the sFlt-1 levels. By one week before the onset of clinical signs, the concentrations approached those observed in end-point specimens. The increases in the sFlt-1 concentration at four weeks, three weeks, two weeks, and one week before the onset of preeclampsia occurred with little change in the mean gestational age of the fetus, and the increase observed between eight weeks and five weeks before the onset of preeclampsia appeared to be about one and a half times the increase that would be expected on the basis of advancing gestational age alone. Five weeks before the onset of preeclampsia, the average concentration in women in whom preeclampsia developed was similar to the concentrations in controls at term, but after this point the sFlt-1 concentration in the women with preeclampsia was higher. More than five weeks before the onset of preeclampsia, no substantial differences were observed between controls and women in whom preeclampsia later developed (Figure 1A). An increase in the sFlt-1 concentration also occurred in normal pregnancies, but it occurred later during gestation and was less pronounced. Figure 1C depicts longitudinally the increase in the sFlt-1 concentration for individual women; the increase occurred during late gestation in the controls but earlier and to a greater extent in the women with preeclampsia.
Gestational Changes in PlGF and VEGF Levels
The gestational pattern in the PlGF level is shown in Figure 2AFigure 2
Concentrations of Placental Growth Factor (PlGF).. The PlGF concentrations in the controls increased during the first two trimesters, peaked at 29 to 32 weeks, and decreased thereafter. The PlGF concentrations in the women with preeclampsia followed a similar pattern but were significantly lower than those in the controls from 13 to 16 weeks onward; at 13 to 16 weeks, the mean level was 90 pg per milliliter in the women who later had preeclampsia and 142 pg per milliliter in the controls (P=0.01). Figure 2B shows the PlGF concentrations in the women in whom preeclampsia developed according to the number of weeks before the onset of preeclampsia. The PlGF concentrations began to decrease 11 to 9 weeks before the onset of preeclampsia, with substantial reductions during the 5 weeks before the onset of hypertension or proteinuria. At about five weeks before the onset of preeclampsia, the average PlGF concentration in women who later had preeclampsia was similar to the average PlGF concentration in controls at term, but after this point, the PlGF concentration in the women with preeclampsia was lower. By one week before the onset of preeclampsia, the concentrations approached those found in women with established preeclampsia (Figure 2B). When specimens obtained within 5 weeks before the onset of preeclampsia were excluded, the differences between the controls and the women who later had preeclampsia were less pronounced at 25 to 28 weeks and 29 to 32 weeks of gestation; no differences were observed at 33 to 36 weeks (Figure 2A).The VEGF concentrations were low throughout pregnancy and did not differ between controls and women who later had preeclampsia, with two exceptions. In specimens obtained at 37 to 41 weeks of gestation, the VEGF levels were lower in the women with preeclampsia (6.7 pg per milliliter, vs. 9.9 pg per milliliter in the controls; P=0.02). In specimens obtained at 21 to 32 weeks, the VEGF levels were lower only if the specimen was obtained within 5 weeks before the onset of preeclampsia (5.1 pg per milliliter, vs. 12.8 pg per milliliter in the controls; P=0.002).
Relationship to Body-Mass Index and Severity of Preeclampsia
Since obesity is an important risk factor for preeclampsia, we examined whether alterations in the body-mass index could account for the elevated sFlt-1 levels and diminished free PlGF levels observed in preeclamptic pregnancy. We performed linear regression analyses of log-transformed sFlt-1 levels and log-transformed free PlGF levels in relation to the body-mass index in control women. Body-mass index was not related to the free PlGF levels at 8 to 20 weeks, 21 to 32 weeks, or 33 to 41 weeks, nor to the sFlt-1 levels at 8 to 20 weeks or 33 to 41 weeks (data not shown); it was inversely related to the sFlt-1 levels at 21 to 32 weeks (estimated beta coefficient for the association with the log-transformed sFlt-1 level, –0.02; P=0.02). Higher sFlt-1 levels and lower PlGF levels in preeclamptic pregnancy, therefore, cannot be explained by greater body-mass index in women in whom preeclampsia develops.
Before the onset of preeclampsia, there were particularly large differences between the concentrations of sFlt-1 and PlGF in controls and those in women who later had early-onset preeclampsia or who had preeclampsia and a small-for-gestational-age infant. Figure 3Figure 3
Mean Concentrations of Soluble fms-like Tyrosine Kinase 1 (sFlt-1) and Placental Growth Factor (PlGF) According to Preeclampsia Status and Severity. shows the concentrations between 21 and 32 weeks of gestation (Figure 3A) and 33 to 41 weeks of gestation (Figure 3B). Alterations in the sFlt-1 and PlGF levels were also more pronounced before the onset of preeclampsia in women who had preeclampsia before term (<37 weeks of gestation) than in women who had an onset of preeclampsia at term (≥37 weeks) (at 21 to 32 weeks: sFlt-1 level, 1672 pg per milliliter in women with preeclampsia before term vs. 935 pg per milliliter in women with preeclampsia at term; P<0.001; PlGF level, 297 vs. 676 pg per milliliter; P<0.001; at 33 to 41 weeks: sFlt-1 level, 8150 vs. 2467 pg per milliliter; P<0.001; PlGF level, 73 vs. 370 pg per milliliter; P=0.05). Furthermore, the sFlt-1 and PlGF levels in specimens obtained before the onset of preeclampsia from women who later had preeclampsia and a small-for-gestational-age infant were significantly different from the concentrations in the women who later had preeclampsia but whose infants were not small for gestational age (at 21 to 32 weeks: sFlt-1 level, 1993 vs. 985 pg per milliliter; P<0.001; PlGF level, 229 vs. 634 pg per milliliter; P<0.001; at 33 to 41 weeks: sFlt-1 level, 4329 vs. 2442 pg per milliliter; P=0.003; PlGF level, 120 vs. 388 pg per milliliter; P=0.009).Odds Ratios for Preeclampsia Associated with Angiogenic Factors
To determine whether the concentrations of sFlt-1 or PlGF in specimens obtained before the onset of clinical signs of preeclampsia were associated with the risk of this condition, we calculated odds ratios for preeclampsia in each quartile of values for sFlt-1 and PlGF in the controls, as compared with the lowest or highest quartile, respectively (Table 2Table 2
Odds Ratios for Preeclampsia at Less Than 37 Weeks of Gestation and at 37 Weeks or More of Gestation According to Quartile of Total sFlt-1 and Quartile of Free PlGF.). We also examined the risk of preeclampsia in the extreme quartiles with respect to all the other quartiles, as follows. For specimens obtained during the second trimester or the early part of the third trimester, the lowest quartile of PlGF was associated with an increased risk of preterm preeclampsia (at <37 weeks' gestation; odds ratio for specimens from weeks 13 to 20, 7.4; 95 percent confidence interval, 1.8 to 30.2; odds ratio for specimens from weeks 21 to 32, 7.9; 95 percent confidence interval, 2.9 to 21.5). A PlGF level in the lowest quartile, however, was not a significant predictor of preeclampsia with an onset at term (≥37 weeks). Associations between the sFlt-1 level and preeclampsia were observed only closer to the onset of disease. An sFlt-1 level in the highest quartile from 21 to 32 weeks of gestation (but not earlier) predicted preterm preeclampsia (odds ratio, 5.1; 95 percent confidence interval, 2.0 to 13.0), and a level in the highest quartile between 33 and 41 weeks (but not earlier) predicted preeclampsia at term (odds ratio, 6.0; 95 percent confidence interval, 2.9 to 12.5). These findings are consistent with the results presented in Figure 1B, which shows that the elevation in the sFlt-1 level occurs largely within the five weeks before the onset of clinical disease. The lowest quartile of VEGF was not predictive of preeclampsia.Discussion
The experimental production of a preeclampsia-like phenotype in rats with the induction of high circulating levels of sFlt-1 raised the possibility that this antiangiogenic factor might have a pathogenic role in preeclampsia.5 Our findings suggest that concentrations of sFlt-1, which were previously reported to be increased in women with established preeclampsia,5,8 begin to increase steeply about five weeks before the onset of clinical disease. Parallel with the increase in the sFlt-1 level, there are decreases in the free PlGF and free VEGF levels, suggesting that the decrease in these factors may be attributable in part to binding by sFlt-1. Women with preterm preeclampsia or preeclampsia and a small-for-gestational-age infant had higher sFlt-1 levels and lower PlGF levels at 21 to 32 weeks and at 33 to 41 weeks than those with an onset of preeclampsia at term or preeclampsia without a small-for-gestational-age infant, respectively.
We have also demonstrated that there is a moderate but significant decrease in the PlGF level beginning early in the second trimester among women in whom preeclampsia later develops, which is consistent with previous observations.11,18-21 Finally, we have shown that women with low concentrations of PlGF during early gestation have a much greater risk of early-onset preeclampsia.
In normotensive pregnancy, the sFlt-1 levels are stable during the early and middle stages of gestation, and there is a steady increase beginning at 33 to 36 weeks. This increase corresponds to the late-gestational decrease in the free PlGF level in normal pregnancy that is reported here and has been observed by others.11,22 During the second trimester, the PlGF concentrations are high and the sFlt-1 concentrations low, creating a proangiogenic state. We speculate that in later gestation, placental vascular growth may be tempered by the increase in the levels of antiangiogenic sFlt-1 and the decrease in the levels of proangiogenic VEGF and PlGF. In women with preeclampsia, sFlt-1 appears to increase earlier in gestation and to reach a higher concentration than it does in controls. Thus, in preeclampsia, the antiangiogenic “brakes” may be applied too soon and too hard — an exaggeration of a normal process governing placental growth and function. A study involving renal biopsies that demonstrated mild glomerular endotheliosis in normal term pregnancy and severe lesions in preeclampsia23 is consistent with the hypothesis that preeclampsia is an exacerbation of the antiangiogenic state of normotensive pregnancy at term.
Since they are not accompanied by reciprocal increases in systemic sFlt-1 levels, diminished PlGF levels early in the pregnancies of women in whom preeclampsia later develops might reflect either less placental production or increased binding to local circulating and membrane-bound receptors. Diminished levels of placental PlGF could play a role in the aberrant cytotrophoblast invasion (“pseudovasculogenesis”) that is characteristic of preeclampsia.24,25 Alterations of the sFlt-1 and PlGF levels appeared to be greater in women who had early-onset preeclampsia and in women with preeclampsia who delivered a small-for-gestational-age infant, suggesting that defective angiogenesis may be especially important in these cases. The VEGF levels were decreased during and within five weeks before established preeclampsia, but low levels were not a significant predictor of future preeclampsia.
Our study has limitations. The data are primarily cross-sectional and do not permit the distinction of subgroups in which the sFlt-1 and PlGF concentrations might be altered even more or not at all. Nevertheless, longitudinal plots of sFlt-1 concentrations in individual women according to the gestational age of the fetus have confirmed the third-trimester increase in the sFlt-1 level in controls and the greater increase in women with preeclampsia. We found the sFlt-1 levels in women with established preeclampsia to be lower than others have reported them to be.5,8 Longer freezer-storage times may have resulted in decreased sFlt-1 levels in our study. A more likely explanation is that the women in our study may have had milder preeclampsia. The mean gestational age of the fetus at the time when specimens were obtained from women with clinical preeclampsia was 38 weeks in this study, as compared with 34 weeks or less in other studies. Finally, we did not examine other complications of pregnancy, such as intrauterine growth restriction in the absence of hypertension or gestational hypertension without proteinuria.
In summary, we have demonstrated a marked increase in the circulating sFlt-1 concentration beginning five weeks before the onset of preeclampsia, accompanied by decreases in the circulating free PlGF and VEGF levels. These findings lend support to the hypothesis that circulating angiogenic proteins may have an important biologic role in preeclampsia. Data from prospective, longitudinal studies in which serial concentrations of sFlt-1 and free PlGF are measured throughout pregnancy are needed to better assess the relevance of these markers to the early identification of preeclampsia and the prediction of its severity.
Supported by funds from the Beth Israel Deaconess Medical Center Obstetrics Department Research Foundation and by grants (DK 64255 and DK 02825, to Dr. Karumanchi) from the National Institutes of Health. The CPEP trial was supported by contracts (N01-HD-1-3121, N01-HD-1-3122, N01-HD-1-3123, N01-HD-1-3124, N01-HD-1-3125, N01-HD-1-3126, N01-HD-3154, and N01-HD-5-3246) with the National Institute of Child Health and Human Development, with cofunding from the National Heart, Lung, and Blood Institute.
Drs. Maynard, Sukhatme, and Karumanchi report being named as coinventors on a pending patent filed by Beth Israel Deaconess Medical Center for the use of angiogenesis-related proteins for the diagnosis and treatment of preeclampsia.
Drs. Levine and Karumanchi contributed equally to the article.
We are indebted to Patricia Moyer for assistance with figures; to Dr. Harold Dvorak, Department of Pathology, Beth Israel Deaconess Medical Center, for helpful suggestions and for his pioneering work in angiogenesis; to the patients who participated in the study; and to the following members of the CPEP Study Group, who assembled the data base and specimen repository: J.C. Hauth, R. Goldenberg, B.S. Stofan (University of Alabama at Birmingham); L.B. Curet, G.M. Joffe, V. Dorato (University of New Mexico at Albuquerque); B.M. Sibai, S.A. Friedman, B.M. Mercer, T. Carr (University of Tennessee at Memphis); P.M. Catalano, A.S. Petrulis, L. Barabach (Case Western Reserve University at MetroHealth Medical Center, Cleveland); C. Morris, S.-L. Jacobson, K. McCracken (Oregon Health Sciences University, Portland); J.R. Esterlitz, M.G. Ewell, D.M. Brown (the Emmes Corporation, Rockville, Md.); R.J. Levine, R. DerSimonian, J.D. Clemens, M.A. Klebanoff, E.G. Raymond, J.G. Rigau-Perez, H. Shifrin (National Institute of Child Health and Human Development); J.A. Cutler, D.E. Bild (National Heart, Lung, and Blood Institute); M. Lindheimer, C. Begg, T. Chalmers, M. Druzin, R. Sokol (Data and Safety Monitoring Board).
Source Information
From the Division of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, Department of Health and Human Services, Bethesda, Md. (R.J.L., L.J.E., K.F.Y., E.F.S.); the Departments of Medicine (S.E.M., F.H.E., V.P.S., S.A.K.) and Obstetrics and Gynecology (K.-H.L., B.P.S., S.A.K.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; Allied Technology Group, Rockville, Md. (C.Q.); the Harvard School of Public Health, Boston (B.P.S.); the Departments of Medicine and Obstetrics, Massachusetts General Hospital and Harvard Medical School, Boston (R.T.); and the Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati (B.M.S.).
Address reprint requests to Dr. Levine at the National Institute of Child Health and Human Development, Bldg. 6100, Rm. 7B03, Bethesda, MD 20892, or at levinerj@mail.nih.gov, or to Dr. Karumanchi at Beth Israel Deaconess Medical Center, 330 Brookline Ave., Dana 517, Boston, MA 02215, or at sananth@bidmc.harvard.edu.
- References
References
1
Walker JJ . Pre-eclampsia. Lancet 2000;356:1260-1265
CrossRef | Web of Science | Medline2
Roberts JM ,Cooper DW . Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357:53-56
CrossRef | Web of Science | Medline3
Cockell AP ,Learmont JG ,Smarason AK ,Redman CW ,Sargent IL ,Poston L . Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Br J Obstet Gynaecol 1997;104:235-240
CrossRef | Medline4
Holzgreve W ,Ghezzi F ,Di Naro E ,Ganshirt D ,Maymon E ,Hahn S . Disturbed feto-maternal cell traffic in preeclampsia. Obstet Gynecol 1998;91:669-672
CrossRef | Web of Science | Medline5
Maynard SE ,Min JY ,Merchan J , et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658
Web of Science | Medline6
Page NM ,Woods RJ ,Gardiner SM , et al. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature 2000;405:797-800
CrossRef | Web of Science | Medline7
Zhou Y ,McMaster M ,Woo K , et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-1423
CrossRef | Web of Science | Medline8
Koga K ,Osuga Y ,Yoshino O , et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348-2351
CrossRef | Web of Science | Medline9
Tsatsaris V ,Goffin F ,Munaut C , et al. Overexpression of the soluble vascular endothelial growth factor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-5563
CrossRef | Web of Science | Medline10
Polliotti BM ,Fry AG ,Saller DN ,Mooney RA ,Cox C ,Miller RK . Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-1274
CrossRef | Web of Science | Medline11
Taylor RN ,Grimwood J ,Taylor RS ,McMaster MT ,Fisher SJ ,North RA . Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-182
CrossRef | Web of Science | Medline12
Eremina V ,Sood M ,Haigh J , et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-716
Web of Science | Medline13
Kabbinavar F ,Hurwitz HI ,Fehrenbacher L , et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) and FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65
CrossRef | Web of Science | Medline14
Yang JC ,Haworth L ,Sherry RM , et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434
Full Text | Web of Science | Medline15
Levine RJ ,Esterlitz JR ,Raymond EG , et al. Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Control Clin Trials 1996;17:442-469
CrossRef | Medline16
Levine RJ ,Hauth JC ,Curet LB , et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69-76
Full Text | Web of Science | Medline17
Zhang J ,Bowes WA Jr . Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population. Obstet Gynecol 1995;86:200-208
CrossRef | Web of Science | Medline18
Tjoa ML ,van Vugt JM ,Mulders MA ,Schutgens RB ,Oudejans CB ,van Wijk IJ . Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001;98:600-607
CrossRef | Web of Science | Medline19
Tidwell SC ,Ho HN ,Chiu WH ,Torry RJ ,Torry DS . Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001;184:1267-1272
CrossRef | Web of Science | Medline20
Su YN ,Lee CN ,Cheng WF ,Shau WY ,Chow SN ,Hsieh FJ . Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001;97:898-904
CrossRef | Web of Science | Medline21
Thadhani R, Mutter W, Wolf M, et al. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 (sFlt-1) and risk for preeclampsia. J Clin Endocrinol Metab (in press).
22
Torry DS ,Wang HS ,Wang TH ,Caudle MR ,Torry RJ . Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:1539-1544
CrossRef | Web of Science | Medline23
Strevens H ,Wide-Swensson D ,Hansen A , et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003;110:831-836
CrossRef | Web of Science | Medline24
Zhou Y ,Damsky CH ,Fisher SJ . Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype: one cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152-2164
CrossRef | Web of Science | Medline25
Torry DS ,Mukherjea D ,Arroyo J ,Torry RJ . Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig 2003;10:178-188
CrossRef | Medline
- Citing Articles (553)
Citing Articles
1
Jimmy Espinoza. (2012) Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. Expert Opinion on Medical Diagnostics1-10
CrossRef2
M. Nasir Uddin, Steven R. Allen, Richard O. Jones, David C. Zawieja, Thomas J. Kuehl. (2012) Pathogenesis of pre-eclampsia: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome. Translational Research
CrossRef3
Eileen R. Fowles, Lorraine O. Walker, C. Nathan Marti, Roberta Jeanne Ruiz, Joel Wommack, Miranda Bryant, SungHun Kim, Gayle M. Timmerman. (2012) Relationships among maternal nutrient intake and placental biomarkers during the 1st trimester in low-income women. Archives of Gynecology and Obstetrics
CrossRef4
Jason J. S. Waugh, Maria C. Smith. 2012. Hypertensive Disorders. , 99-110.
CrossRef5
Stefan Verlohren, Holger Stepan, Ralf Dechend. (2012) Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clinical Science 122:2, 43-52
CrossRef6
Maurizio Mandalà, Natalia Gokina, Carolyn Barron, George Osol. (2012) Endothelial-Derived Hyperpolarization Factor (EDHF) Contributes to PlGF-Induced Dilation of Mesenteric Resistance Arteries from Pregnant Rats. Journal of Vascular Research 49:1, 43-49
CrossRef7
Merzaka Lazdam, Esther F. Davis, Adam J. Lewandowski, Stephanie A. Worton, Yvonne Kenworthy, Brenda Kelly, Paul Leeson. (2012) Prevention of Vascular Dysfunction after Preeclampsia: A Potential Long-Term Outcome Measure and an Emerging Goal for Treatment. Journal of Pregnancy 2012, 1-8
CrossRef8
Satyan Kalkunte, James F. Padbury, Surendra Sharma. 2012. Immunologic Basis of Placental Function and Diseases. , 37-50.
CrossRef9
Eric M. George, Drew Colson, Jeremy Dixon, Ana C. Palei, Joey P. Granger. (2012) Heme Oxygenase-1 Attenuates Hypoxia-Induced sFlt-1 and Oxidative Stress in Placental Villi through Its Metabolic Products CO and Bilirubin. International Journal of Hypertension 2012, 1-6
CrossRef10
Amir Shmueli, Hamutal Meiri, Ron Gonen. (2012) Economic assessment of screening for pre-eclampsia. Prenatal Diagnosisn/a-n/a
CrossRef11
Sanjib Kumar Ghosh, Shashi Raheja, Anita Tuli, Chitra Raghunandan, Sneh Agarwal. (2012) Combination of uterine artery Doppler velocimetry and maternal serum placental growth factor estimation in predicting occurrence of pre-eclampsia in early second trimester pregnancy: a prospective cohort study. European Journal of Obstetrics & Gynecology and Reproductive Biology
CrossRef12
Tu'uhevaha J. Kaitu'u-Lino, Kirsten R. Palmer, Clare L. Whitehead, Elizabeth Williams, Martha Lappas, Stephen Tong. (2012) MMP-14 Is Expressed in Preeclamptic Placentas and Mediates Release of Soluble Endoglin. The American Journal of Pathology
CrossRef13
James M. Roberts, C. Escudero. (2012) The placenta in preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
CrossRef14
Catherine L. Haggerty, Michael E. Seifert, Gong Tang, Jorn Olsen, Debra C. Bass, S. Ananth Karumanchi, Roberta B. Ness. (2012) Second trimester anti-angiogenic proteins and preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
CrossRef15
Kristin Bixel, Michelle Silasi, Carolyn M. Zelop, Kee-Hak Lim, Zsuzsanna Zsengeller, Isaac E. Stillman, Sarosh Rana. (2011) Placental Origins of Angiogenic Dysfunction in Mirror Syndrome. Hypertension in Pregnancy1-7
CrossRef16
Barbara Mikat, Anna Zeller, André Scherag, Karla Drommelschmidt, Rainer Kimmig, Markus Schmidt. (2011) βhCG and PAPP-A in First Trimester: Predictive Factors for Preeclampsia?. Hypertension in Pregnancy1-7
CrossRef17
Colin F. Greineder, Sarah Kohnstamm, Bonnie Ky. (2011) Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models. Current Hypertension Reports 13:6, 436-441
CrossRef18
David O. Bates. (2011) An unexpected tail of VEGF and PlGF in pre-eclampsia. Biochemical Society Transactions 39:6, 1576-1582
CrossRef19
Wenda Ramma, Asif Ahmed. (2011) Is inflammation the cause of pre-eclampsia?. Biochemical Society Transactions 39:6, 1619-1627
CrossRef20
Caren G. Solomon, Ellen W. Seely. (2011) Hypertension in Pregnancy. Endocrinology & Metabolism Clinics of North America 40:4, 847-863
CrossRef21
Jun Zhao, Haiyi Liu, Hui Du, Fuyuan Qiao, Yvqi Li, Xinwei Shi, Xun Gong, Yuanyuan Wu, Qiong Zhou, Jingjing Xu. (2011) Upregulation of sFlt-1 by trophoblasts induces the barrier dysfunction of glomerular endothelial cells. Journal of Huazhong University of Science and Technology [Medical Sciences] 31:6, 815-818
CrossRef22
Sanjib Kumar Ghosh, Shashi Raheja, Anita Tuli, Chitra Raghunandan, Sneh Agarwal. (2011) Association between placental growth factor levels in early onset preeclampsia with the occurrence of postpartum hemorrhage: A prospective cohort study. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
CrossRef23
U.D. Anderson, M.G. Olsson, K.H. Kristensen, B. Åkerström, S.R. Hansson. (2011) Review: Biochemical markers to predict preeclampsia. Placenta
CrossRef24
O. Sanchez, E. Llurba, G. Marsal, C. Dominguez, C. Aulesa, M. A. Sanchez-Duran, M. M. Goya, J. Alijotas-Reig, E. Carreras, L. Cabero. (2011) First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology. Human Reproduction
CrossRef25
Raffaele Napolitano, Alfonso Campanile, Laura Sarno, Antonio Anastasio, Giuseppe M. Maruotti, Maddalena Morlando, Bruno Trimarco, Pasquale Martinelli, Guido Iaccarino. (2011) GRK2 Levels in Umbilical Arteries of Pregnancies Complicated by Gestational Hypertension and Preeclampsia. American Journal of Hypertension
CrossRef26
J. C. P. Kingdom, S. Drewlo. (2011) Is heparin a placental anticoagulant in high-risk pregnancies?. Blood 118:18, 4780-4788
CrossRef27
Giovanna Ogge, Tinnakorn Chaiworapongsa, Roberto Romero, Youssef Hussein, Juan Pedro Kusanovic, Lami Yeo, Chong Jai Kim, Sonia S. Hassan. (2011) Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. Journal of Perinatal Medicine 39:6, 641-652
CrossRef28
Katrin Petzold, Alexander Jank, Renaldo Faber, Holger Stepan. (2011) Relation Between Maternal Angiogenic Factors and Utero-Placental Resistance in Normal First- and Second-Trimester Pregnancies. Hypertension in Pregnancy 30:4, 401-407
CrossRef29
Ga Hyun Son, Jeong Hyeon Kim, Jung Hae Hwang, Young Han Kim, Yong Won Park, Ja Young Kwon. (2011) Urinary Excretion of Nephrin in Patients with Severe Preeclampsia. Hypertension in Pregnancy 30:4, 408-413
CrossRef30
Jessica M. Faupel-Badger, Yuping Wang, S. Ananth Karumanchi, Frank Stanczyk, Michael Pollak, Thomas McElrath, Robert N. Hoover, Rebecca Troisi. (2011) Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes & Control 22:11, 1587-1595
CrossRef31
MARIA PALM, SAMAR BASU, ANDERS LARSSON, LISA WERNROTH, HELENA ÅKERUD, OVE AXELSSON. (2011) A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. Acta Obstetricia et Gynecologica Scandinavica 90:11, 1244-1251
CrossRef32
Zain Al-Safi, Anthony N. Imudia, Lusia C. Filetti, Deslyn T. Hobson, Ray O. Bahado-Singh, Awoniyi O. Awonuga. (2011) Delayed Postpartum Preeclampsia and Eclampsia. Obstetrics & Gynecology 118:5, 1102-1107
CrossRef33
Samantha J. Benton, Yuxiang Hu, Fang Xie, Kenneth Kupfer, Seok-Won Lee, Laura A. Magee, Peter von Dadelszen. (2011) Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. American Journal of Obstetrics and Gynecology 205:5, 469.e1-469.e8
CrossRef34
Neroli S. Sunderland, Sally E. Thomson, Scott J. Heffernan, Shirlene Lim, John Thompson, Robert Ogle, Paul McKenzie, Paul J. Kirwan, Angela Makris, Annemarie Hennessy. (2011) Tumor necrosis factor α induces a model of preeclampsia in pregnant baboons (Papio hamadryas). Cytokine 56:2, 192-199
CrossRef35
BALÁZS STENCZER, ATTILA MOLVAREC, ZOLTÁN VERESH, NÓRA GULLAI, GYULA RICHÁRD NAGY, SZILVIA WALENTIN, JÁNOS SZIJÁRTÓ, JÁNOS RIGÓ. (2011) Circulating levels of the anti-angiogenic thrombospondin 2 are elevated in pre-eclampsia. Acta Obstetricia et Gynecologica Scandinavica 90:11, 1291-1295
CrossRef36
Harvey J. Sugerman. (2011) Hypothesis: Preeclampsia is a venous disease secondary to an increased intra-abdominal pressure. Medical Hypotheses 77:5, 841-849
CrossRef37
V.L. Clifton, M.J. Stark, A. Osei-Kumah, N.A. Hodyl. (2011) Review: The feto-placental unit, pregnancy pathology and impact on long term maternal health. Placenta
CrossRef38
G Rath, R Tripathi. (2011) Angiogenic balance and diagnosis of pre-eclampsia: selecting the right VEGF receptor. Journal of Human Hypertension
CrossRef39
V Jha, P K Aggarwal, N Chandel, V Jain. (2011) Angiogenic balance and diagnosis of pre-eclampsia: selecting the right VEGF receptor. Journal of Human Hypertension
CrossRef40
Aly Youssef, Francesca Righetti, Danila Morano, Nicola Rizzo, Antonio Farina. (2011) Uterine artery Doppler and biochemical markers (PAPP-A, PlGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (>34 weeks) pre-eclampsia. Prenatal Diagnosisn/a-n/a
CrossRef41
Akiko Masuda, Tomoyuki Fujii, Yuki Iwasawa, Kazuhiro Nakamura, Ryunosuke Ohkawa, Koji Igarashi, Shinichi Okudaira, Hitoshi Ikeda, Shiro Kozuma, Junken Aoki, Yutaka Yatomi. (2011) Serum autotaxin measurements in pregnant women: Application for the differentiation of normal pregnancy and pregnancy-induced hypertension. Clinica Chimica Acta 412:21-22, 1944-1950
CrossRef42
K. Fujita, K. Tatsumi, E. Kondoh, Y. Chigusa, H. Mogami, T. Fujii, S. Yura, K. Kakui, I. Konishi. (2011) Differential expression and the anti-apoptotic effect of human placental neurotrophins and their receptors. Placenta 32:10, 737-744
CrossRef43
Balázs Stenczer, Attila Molvarec, Gábor Szabó, András Szarka, Gergely Fügedi, János Szijártó, János Rigó. (2011) Circulating levels of thrombospondin-1 are decreased in HELLP syndrome. Thrombosis Research
CrossRef44
J. Espinoza, A. F. Espinoza. (2011) Pre-eclampsia: a maternal manifestation of a fetal adaptive response?. Ultrasound in Obstetrics & Gynecology 38:4, 367-370
CrossRef45
G. Vandenberghe, I. Mensink, J. W. R. Twisk, M. A. Blankenstein, A. C. Heijboer, J. M. G. van Vugt. (2011) First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia. Prenatal Diagnosis 31:10, 955-961
CrossRef46
Anthony O. Odibo, Katherine R. Goetzinger, Linda Odibo, Alison G. Cahill, George A. Macones, D. Michael Nelson, Dennis J. Dietzen. (2011) First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenatal Diagnosis 31:10, 990-994
CrossRef47
Jessica M. Faupel-Badger, Anne Cathrine Staff, Ravi Thadhani, Camille E. Powe, Nancy Potischman, Robert N. Hoover, Rebecca Troisi. (2011) Maternal angiogenic profile in pregnancies that remain normotensive. European Journal of Obstetrics & Gynecology and Reproductive Biology 158:2, 189-193
CrossRef48
Youichi Aoki, Tatsuo Yamamoto, Chishima Fumihisa, Akikazu Nakamura, Aki Asanuma, Manami Suzuki. (2011) Effect on the Production of Soluble Endoglin from Human Choriocarcinoma Cells by Preeclampsia Sera. American Journal of Reproductive Immunologyno-no
CrossRef49
Keiko Koide, Akihiko Sekizawa, Junko Yotsumoto, Satoshi Miyagami, Kiyotake Ichizuka, Ryu Matsuoka, Takashi Okai. (2011) Role of Epigenetics in the Placenta: Alterations in DNA Promoter Mmethylation and Limprinted Genes. Journal of Mammalian Ova Research 28:3, 103-109
CrossRef50
Franziska Pettit, Mark A. Brown. (2011) The management of pre-eclampsia: what we think we know. European Journal of Obstetrics & Gynecology and Reproductive Biology
CrossRef51
Alexander Jank, Wiebke Schaarschmidt, Holger Stepan. (2011) Effect of steroids on angiogenic factors in pregnant women with HELLP syndrome. Journal of Perinatal Medicine 39:5, 611-613
CrossRef52
Shuenn-Dyh Chang, An-Shine Chao, Hsiu-Huei Peng, Yao-Lung Chang, Chao-Ning Wang, Po-Jen Cheng, Yun-Shien Lee, Angel Chao, Tzu-Hao Wang. (2011) Analyses of placental gene expression in pregnancy-related hypertensive disorders. Taiwanese Journal of Obstetrics and Gynecology 50:3, 283-291
CrossRef53
Jie Yu, Juanjuan Wu, Indrani C. Bagchi, Milan K. Bagchi, Neil Sidell, Robert N. Taylor. (2011) Disruption of gap junctions reduces biomarkers of decidualization and angiogenesis and increases inflammatory mediators in human endometrial stromal cell cultures. Molecular and Cellular Endocrinology 344:1-2, 25-34
CrossRef54
Shih-Pin Chen, Jong-Ling Fuh, Shuu-Jiun Wang. (2011) Reversible cerebral vasoconstriction syndrome: current and future perspectives. Expert Review of Neurotherapeutics 11:9, 1265-1276
CrossRef55
Evgeny V Sidorov, Wuwei Feng, Louis R Caplan. (2011) Stroke in pregnant and postpartum women. Expert Review of Cardiovascular Therapy 9:9, 1235-1247
CrossRef56
Véronique Taché, D. Yvette LaCoursiere, Aasia Saleemuddin, Mana M. Parast. (2011) Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity. Human Pathology 42:9, 1283-1288
CrossRef57
Etienne Ciantar, James J Walker. (2011) Pre-eclampsia, severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelets syndrome: what is new?. Women's Health 7:5, 555-569
CrossRef58
K.A. Groesch, R.J. Torry, A.C. Wilber, R. Abrams, A. Bieniarz, L.J. Guilbert, D.S. Torry. (2011) Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblast. Placenta
CrossRef59
Mary A. Vadnais, Sarosh Rana, Hayley S. Quant, Saira Salahuddin, Laura E. Dodge, Kee-Hak Lim, S. Ananth Karumanchi, Michele R. Hacker. (2011) The impact of magnesium sulfate therapy on angiogenic factors in preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
CrossRef60
Ulla B. Knudsen, Camilla S. Kronborg, Peter von Dadelszen, Ken Kupfer, Seok-Won Lee, Erik Vittinghus, Jim G. Allen, Christopher W. Redman. (2011) A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
CrossRef61
Samantha J. Benton, Yuxiang Hu, Fang Xie, Kenneth Kupfer, Seok-Won Lee, Laura A. Magee, Peter von Dadelszen. (2011) Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?. American Journal of Obstetrics and Gynecology
CrossRef62
Daniel C. Cho, Michael B. Atkins. (2011) Future Directions in Renal Cell Carcinoma: 2011 and Beyond. Hematology/Oncology Clinics of North America 25:4, 917-935
CrossRef63
Hyun-Joo Seol, Min-Jeong Oh, Hai-Joong Kim. (2011) Endothelin-1 Expression by Vascular Endothelial Growth Factor in Human Umbilical Vein Endothelial Cells and Aortic Smooth Muscle Cells. Hypertension in Pregnancy 30:3, 295-301
CrossRef64
B. A. Mercadal, R. Imbert, I. Demeestere, Y. Englert, A. Delbaere. (2011) Pregnancy outcome after oocyte donation in patients with Turner's syndrome and partial X monosomy. Human Reproduction 26:8, 2061-2068
CrossRef65
Ali Gedikbasi, Kazim Oztarhan, Ziya Gunenc, Gokhan Yildirim, Oguz Arslan, Dogukan Yildirim, Yavuz Ceylan. (2011) Preeclampsia Due to Fetal Non-immune Hydrops: Mirror Syndrome and Review of Literature. Hypertension in Pregnancy 30:3, 322-330
CrossRef66
Shakila Thangaratinam, Josie Langenveld, Ben W. Mol, Khalid S. Khan. (2011) Prediction and primary prevention of pre-eclampsia. Best Practice & Research Clinical Obstetrics & Gynaecology 25:4, 419-433
CrossRef67
A Eskild, LJ Vatten. (2011) Placental weight and excess postpartum haemorrhage: a population study of 308 717 pregnancies. BJOG: An International Journal of Obstetrics & Gynaecology 118:9, 1120-1125
CrossRef68
S.V. Ramesar, I. Mackraj, P. Gathiram, J. Moodley. (2011) Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague–Dawley rats. European Journal of Obstetrics & Gynecology and Reproductive Biology 157:2, 136-140
CrossRef69
Neil CAMPBELL, Robert OGLE, Charlene THORNTON, Annemarie HENNESSY, Jason ABBOTT. (2011) Urinary placental growth factor differentiates the hypertensive disorders of pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecologyno-no
CrossRef70
RANGEEN RAFIK HAMAD, MARIA J. ERIKSSON, ELISABETH BERG, ANDERS LARSSON, KATARINA BREMME. (2011) Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia. Acta Obstetricia et Gynecologica Scandinavicano-no
CrossRef71
Sanjib Kumar Ghosh, Shashi Raheja, Anita Tuli, Chitra Raghunandan, Sneh Agarwal. (2011) Serum PLGF as a potential biomarker for predicting the onset of preeclampsia. Archives of Gynecology and Obstetrics
CrossRef72
Tania Nevers, Satyan Kalkunte, Surendra Sharma. (2011) Uterine Regulatory T cells, IL-10 and Hypertension. American Journal of Reproductive Immunology 66, 88-92
CrossRef73
Michelle A. Hladunewich, Franz Schaefer. (2011) Proteinuria in Special Populations: Pregnant Women and Children. Advances in Chronic Kidney Disease 18:4, 267-272
CrossRef74
Bonnie Ky, Benjamin French, Kosha Ruparel, Nancy K. Sweitzer, James C. Fang, Wayne C. Levy, Douglas B. Sawyer, Thomas P. Cappola. (2011) The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. Journal of the American College of Cardiology 58:4, 386-394
CrossRef75
Christopher Redman. (2011) L2. Clinical utility of placental growth factor – Pathological insights from commercial assays. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1:3-4, 239
CrossRef76
Andrea Schanz, Virginia D. Winn, Susan J. Fisher, Marion Blumenstein, Christian Heiss, Alexandra P. Hess, Jan S. Kruessel, Michael Mcmaster, Robyn A. North. (2011) Pre-eclampsia is associated with elevated CXCL12 levels in placental syncytiotrophoblasts and maternal blood. European Journal of Obstetrics & Gynecology and Reproductive Biology 157:1, 32-37
CrossRef77
France Boyaud, Nicolas Inguimbert. (2011) Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475). Expert Opinion on Therapeutic Patents 21:6, 971-975
CrossRef78
Michelle Silasi, Sarosh Rana, Camille Powe, Bruce Cohen, Kee-Hak Lim, Zsuzsanna K. Zsengellér, S. Ananth Karumanchi, Isaac E. Stillman. (2011) Placental expression of angiogenic factors in Trisomy 13. American Journal of Obstetrics and Gynecology 204:6, 546.e1-546.e4
CrossRef79
Lai Wa Law, Daljit Singh Sahota, Lin Wai Chan, Min Chen, Tze Kin Lau, Tak Yeung Leung. (2011) Serum placental growth factor and fms-like tyrosine kinase 1 during first trimester in Chinese women with pre-eclampsia – a case–control study. Journal of Maternal-Fetal and Neonatal Medicine 24:6, 808-811
CrossRef80
Karin Leslie, Basky Thilaganathan, Aris Papageorghiou. (2011) Early prediction and prevention of pre-eclampsia. Best Practice & Research Clinical Obstetrics & Gynaecology 25:3, 343-354
CrossRef81
Xin Luo, Zhen-wei Yao, Hong-bo Qi, Dan-dan Liu, Guo-qing Chen, Shuai Huang, Qing-shu Li. (2011) Gadd45α as an upstream signaling molecule of p38 MAPK triggers oxidative stress-induced sFlt-1 and sEng upregulation in preeclampsia. Cell and Tissue Research 344:3, 551-565
CrossRef82
Ivraym B. Barsoum, Stephen J. Renaud, Charles H. Graham. (2011) Glyceryl Trinitrate Inhibits Hypoxia-Induced Release of Soluble fms-Like Tyrosine Kinase-1 and Endoglin from Placental Tissues. The American Journal of Pathology 178:6, 2888-2896
CrossRef83
Ulrik Dolberg Anderson, Magnus G. Olsson, Sigurbjörg Rutardóttir, Magnus Centlow, Karl Heby Kristensen, Per Erik Isberg, Baskaran Thilaganathan, Bo Åkerström, Stefan R. Hansson. (2011) Fetal hemoglobin and α1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia. American Journal of Obstetrics and Gynecology 204:6, 520.e1-520.e5
CrossRef84
Adam C. Urato, Errol R. Norwitz. (2011) A guide towards pre-pregnancy management of defective implantation and placentation. Best Practice & Research Clinical Obstetrics & Gynaecology 25:3, 367-387
CrossRef85
J. Yu, C. Z. Shixia, Y. Wu, T. Duan. (2011) Inhibin A, activin A, placental growth factor and uterine artery Doppler pulsatility index in the prediction of pre-eclampsia. Ultrasound in Obstetrics & Gynecology 37:5, 528-533
CrossRef86
Mark J. Wehrum, Irina A. Buhimschi, Carolyn Salafia, Stephen Thung, Mert O. Bahtiyar, Erica F. Werner, Katherine H. Campbell, Christine Laky, Anna K. Sfakianaki, Guomao Zhao, Edmund F. Funai, Catalin S. Buhimschi. (2011) Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. American Journal of Obstetrics and Gynecology 204:5, 411.e1-411.e11
CrossRef87
Egle Bytautiene, Esther Tamayo, Talar Kechichian, Nathan Drever, Phyllis Gamble, Gary D.V. Hankins, George R. Saade. (2011) Prepregnancy obesity and sFlt1-induced preeclampsia in mice: developmental programming model of metabolic syndrome. American Journal of Obstetrics and Gynecology 204:5, 398.e1-398.e8
CrossRef88
Alba Munoz-Suano, Alexander B. Hamilton, Alexander G. Betz. (2011) Gimme shelter: the immune system during pregnancy. Immunological Reviews 241:1, 20-38
CrossRef89
Thomas F. McElrath, Raina Nakova Fichorova, Elizabeth N. Allred, Jonathan L. Hecht, Mahmoud A. Ismail, Huaiping Yuan, Alan Leviton. (2011) Blood protein profiles of infants born before 28 weeks differ by pregnancy complication. American Journal of Obstetrics and Gynecology 204:5, 418.e1-418.e12
CrossRef90
Athar H. Siddiqui, Roxanna A. Irani, Yujin Zhang, Yingbo Dai, Sean C. Blackwell, Susan M. Ramin, Rodney E. Kellems, Yang Xia. (2011) Recombinant Vascular Endothelial Growth Factor 121 Attenuates Autoantibody-Induced Features of Pre-eclampsia in Pregnant Mice. American Journal of Hypertension 24:5, 606-612
CrossRef91
Alev Atis, Yavuz Aydin, Elif Basol, Semih Kaleli, Fatma Turgay, Nimet Goker. (2011) PAPP-A levels of late pregnancy in preeclampsia and HELLP syndrome. Archives of Gynecology and Obstetrics
CrossRef92
Marie Bolin, Peter Åkerud, Agneta Hansson, Helena Åkerud. (2011) Histidine-Rich Glycoprotein as an Early Biomarker of Preeclampsia. American Journal of Hypertension 24:4, 496-501
CrossRef93
Feng Yang, Chen Jin, Yong-jian Jiang, Ji Li, Yang Di, De-Liang Fu. (2011) Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Expert Review of Anticancer Therapy 11:4, 541-549
CrossRef94
Mohamed Nabih El-Gharib, Ma Morad. (2011) Maternal serum inhibin-A for predicting preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine 24:4, 595-599
CrossRef95
Salley G. Pels, Michael J. Paidas. (2011) Microangiopathic Disorders in Pregnancy. Hematology/Oncology Clinics of North America 25:2, 311-322
CrossRef96
Sylwia Kuc, Esther J. Wortelboer, Bas B. van Rijn, Arie Franx, Gerard H. A. Visser, Peter C. J. I. Schielen. (2011) Evaluation of 7 Serum Biomarkers and Uterine Artery Doppler Ultrasound for First-Trimester Prediction of Preeclampsia: A Systematic Review. Obstetrical & Gynecological Survey 66:4, 225-239
CrossRef97
Jamie A. Bastek, Amy G. Brown, Lauren Anton, Sindhu K. Srinivas, Antonietta D'addio, Michal A. Elovitz. (2011) Biomarkers of inflammation and placental dysfunction are associated with subsequent preterm birth. Journal of Maternal-Fetal and Neonatal Medicine 24:4, 600-605
CrossRef98
Olfat Gamil Shaker, Hany Shehata. (2011) Early Prediction of Preeclampsia in High-Risk Women. Journal of Women's Health 20:4, 539-544
CrossRef99
Attila Molvarec, Sandra M. Blois, Balázs Stenczer, Gergely Toldi, Irene Tirado-Gonzalez, Mika Ito, Tomoko Shima, Satoshi Yoneda, Barna Vásárhelyi, János Rigó, Shigeru Saito. (2011) Peripheral blood galectin-1-expressing T and natural killer cells in normal pregnancy and preeclampsia. Clinical Immunology 139:1, 48-56
CrossRef100
Oskar Zakiyanov, Marta Kalousová, Tomáš Zima, Vladimír Tesař. (2011) Placental Growth Factor in Patients with Decreased Renal Function. Renal Failure 33:3, 291-297
CrossRef101
Medhat Alberry, Victoria Bills, Peter Soothill. (2011) An update on pre-eclampsia prediction research. The Obstetrician & Gynaecologist 13:2, 79-85
CrossRef102
Leandro De Oliveira, Niels Olsen S. Câmara, José C. Peraçoli, Maria T. Peraçoli, Antonio F. Moron, Nelson Sass. (2011) sFlt-1 and IP-10 in women with early-onset preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1:2, 129-131
CrossRef103
P K Aggarwal, N Chandel, V Jain, V Jha. (2011) The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. Journal of Human Hypertension
CrossRef104
G Rath, R Tripathi. (2011) VEGF and its soluble receptor VEGFR-2 in hypertensive disorders during pregnancy: the Indian scenario. Journal of Human Hypertension
CrossRef105
Colleen Glyde Julian. (2011) High Altitude During Pregnancy. Clinics in Chest Medicine 32:1, 21-31
CrossRef106
Satyan Kalkunte, Tania Nevers, Wendy E. Norris, Surendra Sharma. (2011) Vascular IL-10: a protective role in preeclampsia. Journal of Reproductive Immunology 88:2, 165-169
CrossRef107
Yannick Bacq. (2011) Liver diseases unique to pregnancy: A 2010 update. Clinics and Research in Hepatology and Gastroenterology 35:3, 182-193
CrossRef108
G. Valdés, J. Corthorn. (2011) Review: The angiogenic and vasodilatory utero-placental network. Placenta 32, S170-S175
CrossRef109
Ana Bertha Zavalza-Gómez. (2011) Obesity and oxidative stress: a direct link to preeclampsia?. Archives of Gynecology and Obstetrics 283:3, 415-422
CrossRef110
Brett Young, Michele R. Hacker, Sarosh Rana. (2011) Physicians' Knowledge of Future Vascular Disease in Women with Preeclampsia. Hypertension in Pregnancy1-9
CrossRef111
T. Cindrova-Davies, D. A. Sanders, G. J. Burton, D. S. Charnock-Jones. (2011) Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovascular Research 89:3, 671-679
CrossRef112
I. Cetin, B. Huppertz, G. Burton, H. Cuckle, R. Gonen, O. Lapaire, L. Mandia, K. Nicolaides, C. Redman, P. Soothill, K. Spencer, B. Thilaganathan, D. Williams, H. Meiri. (2011) Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?. Placenta 32, S4-S16
CrossRef113
Chikako Hirashima, Akihide Ohkuchi, Kayo Takahashi, Hirotada Suzuki, Mika Yoshida, Takako Ohmaru, Kazuo Eguchi, Haruko Ariga, Shigeki Matsubara, Mitsuaki Suzuki. (2011) Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors. Hypertension Research 34:2, 212-217
CrossRef114
Y.-I. Grimpel, V. Kivity, A. Cohen, H. Meiri, M. Sammar, R. Gonen, B. Huppertz. (2011) Effects of calcium, magnesium, low-dose aspirin and low-molecular-weight heparin on the release of PP13 from placental explants. Placenta 32, S55-S64
CrossRef115
Simcha Yagel. (2011) Angiogenesis in gestational vascular complications. Thrombosis Research 127, S64-S66
CrossRef116
Dorrith Schonkeren, Marie-Louise van der Hoorn, Padmini Khedoe, Godelieve Swings, Els van Beelen, Frans Claas, Cees van Kooten, Emile de Heer, Sicco Scherjon. (2011) Differential Distribution and Phenotype of Decidual Macrophages in Preeclamptic versus Control Pregnancies. The American Journal of Pathology 178:2, 709-717
CrossRef117
ANNEMARIE HENNESSY, ANGELA MAKRIS. (2011) Preeclamptic nephropathy. Nephrology 16:2, 134-143
CrossRef118
Shraddha V. Bhadada, Bhoomika R. Goyal, Mayur M. Patel. (2011) Angiogenic targets for potential disorders. Fundamental & Clinical Pharmacology 25:1, 29-47
CrossRef119
W. Hochholzer, T. Reichlin, C. Stelzig, K. Hochholzer, J. Meissner, T. Breidthardt, M. Reiter, B. Duehsler, H. Freidank, K. Winkler, R. Twerenbold, C. Mueller. (2011) Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. European Heart Journal 32:3, 326-335
CrossRef120
Hui Du, Haiyi Liu, Jun Zhao, Yuanyuan Wu, Xun Gong, Qiong Zhou, jingjing Xu, Yuqi Li, Xinwei Shi, Fuyuan Qiao. (2011) Effects of maternal serum on permeability of glomerular endothelial cell membrane. Journal of Huazhong University of Science and Technology [Medical Sciences] 31:1, 17-20
CrossRef121
H Sallinen, M Anttila, O Gröhn, J Koponen, K Hämäläinen, I Kholova, V-M Kosma, S Heinonen, K Alitalo, S Ylä-Herttuala. (2011) Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice. Cancer Gene Therapy 18:2, 100-109
CrossRef122
Edi Vaisbuch, Janice E. Whitty, Sonia S. Hassan, Roberto Romero, Juan Pedro Kusanovic, David B. Cotton, Yoram Sorokin, S. Ananth Karumanchi. (2011) Circulating angiogenic and antiangiogenic factors in women with eclampsia. American Journal of Obstetrics and Gynecology 204:2, 152.e1-152.e9
CrossRef123
Anitha Kilari, Savita Mehendale, Hemlata Pisal, Tushar Panchanadikar, Anvita Kale, Sadhana Joshi. (2011) Nerve growth factor, birth outcome and pre-eclampsia. International Journal of Developmental Neuroscience 29:1, 71-75
CrossRef124
Anna-Karin Wikström, Olof Stephansson, Sven Cnattingius. (2011) Previous preeclampsia and risks of adverse outcomes in subsequent nonpreeclamptic pregnancies. American Journal of Obstetrics and Gynecology 204:2, 148.e1-148.e6
CrossRef125
Asif Ahmed. (2011) New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thrombosis Research 127, S72-S75
CrossRef126
Xiaoping Qing, Patricia B Redecha, Melissa A Burmeister, Stephen Tomlinson, Vivette D D'Agati, Robin L Davisson, Jane E Salmon. (2011) Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney International 79:3, 331-339
CrossRef127
K. Kumasawa, M. Ikawa, H. Kidoya, H. Hasuwa, T. Saito-Fujita, Y. Morioka, N. Takakura, T. Kimura, M. Okabe. (2011) From the Cover: Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proceedings of the National Academy of Sciences 108:4, 1451-1455
CrossRef128
Kirk P. Conrad. (2011) Emerging Role of Relaxin in the Maternal Adaptations to Normal Pregnancy: Implications for Preeclampsia. Seminars in Nephrology 31:1, 15-32
CrossRef129
Michelle A. Josephson, Dianne B. McKay. (2011) Pregnancy and Kidney Transplantation. Seminars in Nephrology 31:1, 100-110
CrossRef130
Anne Cathrine Staff. (2011) Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1:1, 28-42
CrossRef131
Sharon E. Maynard, S. Ananth Karumanchi. (2011) Angiogenic Factors and Preeclampsia. Seminars in Nephrology 31:1, 33-46
CrossRef132
Haruki Nishizawa, Sayuri Ota, Machiko Suzuki, Takema Kato, Takao Sekiya, Hiroki Kurahashi, Yasuhiro Udagawa. (2011) Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reproductive Biology and Endocrinology 9:1, 107
CrossRef133
Manuel V. Blanco, Hilda R. Vega, Rodolfo Giuliano, Daniel R. Grana, Francisco Azzato, Jorge Lerman, Jose Milei. (2011) Histomorphometry of Umbilical Cord Blood Vessels in Preeclampsia. The Journal of Clinical Hypertension 13:1, 30-34
CrossRef134
Berthold Huppertz. (2011) Trophoblast differentiation, fetal growth restriction and preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1:1, 79-86
CrossRef135
K.- A. Wathen, J. Sarvela, F. Stenman, U.- H. Stenman, P. Vuorela. (2011) Changes in serum concentrations of soluble vascular endothelial growth factor receptor-1 after pregnancy. Human Reproduction 26:1, 221-226
CrossRef136
S. Guller, Z. Tang, Y.Y. Ma, S. Di Santo, R. Sager, H. Schneider. (2011) Protein composition of microparticles shed from human placenta during placental perfusion: Potential role in angiogenesis and fibrinolysis in preeclampsia. Placenta 32:1, 63-69
CrossRef137
Giuseppe Castellano, Vincenzo Losappio, Loreto Gesualdo. (2011) Update on Pregnancy in Chronic Kidney Disease. Kidney and Blood Pressure Research 34:4, 253-260
CrossRef138
Tiina Podymow, Phyllis August. (2011) Antihypertensive Drugs in Pregnancy. Seminars in Nephrology 31:1, 70-85
CrossRef139
Ham Bak Lee, Ki Cheol Kil, Sun Young Nam, Jae Eun Shin, Ju Young Cheon, Young Lee. (2011) Clinical usefulness of soluble fms-like tyrosine kinase 1, soluble endoglin and placental growth factor in Korean women with preeclampsia. Korean Journal of Obstetrics 54:5, 229
CrossRef140
Masabumi SHIBUYA. (2011) Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proceedings of the Japan Academy, Series B 87:4, 167-178
CrossRef141
Kiran B. Tam Tam, Babbette Lamarca, Marietta Arany, Kathy Cockrell, Lillian Fournier, Sydney Murphy, James N. Martin, Joey P. Granger. (2011) Role of Reactive Oxygen Species During Hypertension in Response to Chronic Antiangiogenic Factor (sFlt-1) Excess in Pregnant Rats. American Journal of Hypertension 24:1, 110-113
CrossRef142
Sonia Nava-Salazar, Elly N Sánchez-Rodríguez, C Mendoza-Rodríguez, Carlos Moran, Juan F Romero-Arauz, Marco A Cerbón. (2011) Polymorphisms in the hypoxia-inducible factor 1 alpha gene in Mexican patients with preeclampsia: A case-control study. BMC Research Notes 4:1, 68
CrossRef143
Shakil Ahmad, Peter W Hewett, Bahjat Al-Ani, Samir Sissaoui, Takeshi Fujisawa, Melissa J Cudmore, Asif Ahmed. (2011) Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vascular Cell 3:1, 15
CrossRef144
Roxanna A. Irani, Yang Xia. (2011) Renin Angiotensin Signaling in Normal Pregnancy and Preeclampsia. Seminars in Nephrology 31:1, 47-58
CrossRef145
Julie S. Rhee, Brett C. Young, Sarosh Rana. (2011) Angiogenic Factors and Renal Disease in Pregnancy. Case Reports in Obstetrics and Gynecology 2011, 1-4
CrossRef146
Isha Agarwal, S. Ananth Karumanchi. (2011) Preeclampsia and the anti-angiogenic state. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1:1, 17-21
CrossRef147
B. Anne Croy, Suzanne D. Burke, Valerie F. Barrette, Jianhong Zhang, Kota Hatta, Graeme N. Smith, Juares Bianco, Aureo T. Yamada, Michael A. Adams. (2011) Identification of the primary outcomes that result from deficient spiral arterial modification in pregnant mice. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health 1:1, 87-94
CrossRef148
Marni Jacobs, Natasha Nassar, Christine L Roberts, Ruth Hadfield, Jonathan M Morris, Anthony W Ashton. (2011) Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reproductive Biology and Endocrinology 9:1, 77
CrossRef149
Mitsuko Furuya, Kentaro Kurasawa, Kiyotaka Nagahama, Kae Kawachi, Akinori Nozawa, Tsuneo Takahashi, Ichiro Aoki. (2011) Disrupted Balance of Angiogenic and Antiangiogenic Signalings in Preeclampsia. Journal of Pregnancy 2011, 1-10
CrossRef150
Kevin S. Heffernan, Jeffrey T. Kuvin, Ayan R. Patel, Richard H. Karas, Navin K. Kapur. (2011) Endothelial Function and Soluble Endoglin in Smokers With Heart Failure. Clinical Cardiologyn/a-n/a
CrossRef151
Susan R Kahn, Nisha D Almeida, Helen McNamara, Gideon Koren, Jacques Genest, Mourad Dahhou, Robert W Platt, Michael S Kramer. (2011) Smoking in preeclamptic women is associated with higher birthweight for gestational age and lower soluble fms-like tyrosine kinase-1 levels: a nested case control study. BMC Pregnancy and Childbirth 11:1, 91
CrossRef152
Jennifer E. Fugate, Alejandro A. Rabinstein. 2011. Postpartum Angiopathy and Related Disorders. , 69-77.
CrossRef153
Ana Sofia Cerdeira, S. Ananth Karumanchi. 2011. Biomarkers in Preeclampsia. , 385-426.
CrossRef154
Reshef Tal, Aviv Shaish, Iris Barshack, Silvia Polak-Charcon, Arnon Afek, Alexander Volkov, Boris Feldman, Camila Avivi, Dror Harats. (2010) Effects of Hypoxia-Inducible Factor-1α Overexpression in Pregnant Mice. The American Journal of Pathology 177:6, 2950-2962
CrossRef155
Annabel C. Martin, Mark A. Brown. (2010) Could uric acid have a pathogenic role in pre-eclampsia?. Nature Reviews Nephrology 6:12, 744-748
CrossRef156
J.B. Puschett, E. Agunanne, M.N. Uddin. (2010) Marinobufagenin, resibufogenin and preeclampsia. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1802:12, 1246-1253
CrossRef157
Angela Tincani, Ilaria Cavazzana, Tamara Ziglioli, Andrea Lojacono, Valentina Angelis, Pierluigi Meroni. (2010) Complement Activation and Pregnancy Failure. Clinical Reviews in Allergy & Immunology 39:3, 153-159
CrossRef158
Attila Molvarec, Mika Ito, Tomoko Shima, Satoshi Yoneda, Gergely Toldi, Balázs Stenczer, Barna Vásárhelyi, János Rigó, Shigeru Saito. (2010) Decreased proportion of peripheral blood vascular endothelial growth factor–expressing T and natural killer cells in preeclampsia. American Journal of Obstetrics and Gynecology 203:6, 567.e1-567.e8
CrossRef159
Antonio Farina, Cinzia Zucchini, Akihiko Sekizawa, Yuditiya Purwosunu, Paola de Sanctis, Giuseppe Santarsiero, Nicola Rizzo, Danila Morano, Takashi Okai. (2010) Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. American Journal of Obstetrics and Gynecology 203:6, 575.e1-575.e7
CrossRef160
Linda Dexlin-Mellby, Anna Sandström, Magnus Centlow, Sara Nygren, Stefan R. Hansson, Carl A. K. Borrebaeck, Christer Wingren. (2010) Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays. PROTEOMICS - Clinical Applications 4:10-11, 794-807
CrossRef161
A Eskild, LJ Vatten. (2010) Do pregnancies with pre-eclampsia have smaller placentas? A population study of 317 688 pregnancies with and without growth restriction in the offspring. BJOG: An International Journal of Obstetrics & Gynaecology 117:12, 1521-1526
CrossRef162
Satyan Kalkunte, Roland Boij, Wendy Norris, Jennifer Friedman, Zhongbin Lai, Jonathan Kurtis, Kee-Hak Lim, James F. Padbury, Leif Matthiesen, Surendra Sharma. (2010) Sera from Preeclampsia Patients Elicit Symptoms of Human Disease in Mice and Provide a Basis for an in Vitro Predictive Assay. The American Journal of Pathology 177:5, 2387-2398
CrossRef163
O. Pourrat, F. Pierre. (2010) La consultation médicale après une pré-éclampsie : pourquoi ? Pour qui ? Quand ? Comment ? Pour trouver quoi ?. La Revue de Médecine Interne 31:11, 766-771
CrossRef164
Alexandre Hertig, Philippe Liere. (2010) New markers in preeclampsia. Clinica Chimica Acta 411:21-22, 1591-1595
CrossRef165
Hisashi Masuyama, Yuji Hiramatsu. (2010) Angiogenic proteins and adipocytokines as markers for prediction of preeclampsia. Expert Review of Obstetrics & Gynecology 5:6, 717-725
CrossRef166
Emily S. Robinson, Eliyahu V. Khankin, S. Ananth Karumanchi, Benjamin D. Humphreys. (2010) Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker. Seminars in Nephrology 30:6, 591-601
CrossRef167
Vera Eremina, Susan E. Quaggin. (2010) Biology of Anti-Angiogenic Therapy–Induced Thrombotic Microangiopathy. Seminars in Nephrology 30:6, 582-590
CrossRef168
Ulrich Pecks, Franka Seidenspinner, Claudia Röwer, Toralf Reimer, Werner Rath, Michael O. Glocker. (2010) Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: A strategy to distinguish patients with preeclampsia from matching control individuals. Journal of the American Society for Mass Spectrometry 21:10, 1699-1711
CrossRef169
Soo Yeon Han, Jong Kwan Jun, Cha-Hui Lee, Joong Shin Park, Hee Chul Syn. (2010) Angiopoietin-2: A Promising Indicator for the Occurrence of Severe Preeclampsia. Hypertension in Pregnancy1-11
CrossRef170
Manish Maski, Sarosh Rana, S. Ananth Karumanchi. 2010. Biomarkers in Obstetric Medicine. , 323-353.
CrossRef171
Errol R. Norwitz, Julian N. Robinson. 2010. Pregnancy-Induced Physiologic Alterations. , 30-52.
CrossRef172
Joel Moake, Kelty R. Baker. 2010. Thrombotic Thrombocytopenic Purpura, Hemolytic-Uremic Syndrome, and HELLP. , 407-424.
CrossRef173
Attila Molvarec, András Szarka, Szilvia Walentin, Endre Szűcs, Bálint Nagy, János Rigó. (2010) Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertension Research 33:9, 892-898
CrossRef174
Eric M George, Joey P Granger. (2010) Recent insights into the pathophysiology of preeclampsia. Expert Review of Obstetrics & Gynecology 5:5, 557-566
CrossRef175
Ekaterina Maidji, Giovanni Nigro, Takako Tabata, Susan McDonagh, Naoki Nozawa, Stephen Shiboski, Stefania Muci, Maurizio M. Anceschi, Natali Aziz, Stuart P. Adler, Lenore Pereira. (2010) Antibody Treatment Promotes Compensation for Human Cytomegalovirus-Induced Pathogenesis and a Hypoxia-Like Condition in Placentas with Congenital Infection. The American Journal of Pathology 177:3, 1298-1310
CrossRef176
Vivek Shenoy, Keizo Kanasaki, Raghu Kalluri. (2010) Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends in Endocrinology & Metabolism 21:9, 529-536
CrossRef177
Daniel B. DiGiulio, MariaTeresa Gervasi, Roberto Romero, Shali Mazaki-Tovi, Edi Vaisbuch, Juan Pedro Kusanovic, Kimberley S. Seok, Ricardo Gómez, Pooja Mittal, Francesca Gotsch, Tinnakorn Chaiworapongsa, Enrique Oyarzún, Chong Jai Kim, David A. Relman. (2010) Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. Journal of Perinatal Medicine 38:5, 503-513
CrossRef178
Olav Lapaire, Andrew Shennan, Holger Stepan. (2010) The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. European Journal of Obstetrics & Gynecology and Reproductive Biology 151:2, 122-129
CrossRef179
H. Boulanger, S. Ahriz-Saksi, D. Drouin, E. Daugas, N. Berkane, G. Lefevre. (2010) Anti-angiogenic assay assists fetal extraction decision in a case of pre-eclampsia suspicion?. NDT Plus 3:4, 427-428
CrossRef180
Joanna L James, Guy S Whitley, Judith E Cartwright. (2010) Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. The Journal of Pathology 221:4, 363-378
CrossRef181
Sarah Nechuta, Nigel Paneth, Ellen M. Velie. (2010) Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature. Cancer Causes & Control 21:7, 967-989
CrossRef182
T. Hawighorst, W. Stein, C. Gründker, G. Emons. (2010) Angiogenese in Reproduktionsmedizin und gynäkologischer Onkologie. Der Gynäkologe 43:7, 595-600
CrossRef183
Ana Sofia Cerdeira, S. Ananth Karumanchi. (2010) Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia. Scandinavian Journal of Clinical & Laboratory Investigation 70:s242, 73-78
CrossRef184
A.M. Lynch, J.E. Salmon. (2010) Dysregulated Complement Activation as a Common Pathway of Injury in Preeclampsia and Other Pregnancy Complications. Placenta 31:7, 561-567
CrossRef185
Maged M. Costantine, Esther Tamayo, Fangxian Lu, Egle Bytautiene, Monica Longo, Gary D. V. Hankins, George R. Saade. (2010) Using Pravastatin to Improve the Vascular Reactivity in a Mouse Model of Soluble Fms-Like Tyrosine Kinase-1–Induced Preeclampsia. Obstetrics & Gynecology 116:1, 114-120
CrossRef186
Jimmy Espinoza, John E. Uckele, Robert A. Starr, David E. Seubert, Andres F. Espinoza, Stanley M. Berry. (2010) Angiogenic imbalances: the obstetric perspective. American Journal of Obstetrics and Gynecology 203:1, 17.e1-17.e8
CrossRef187
David A. Miller. 2010. Hypertension in Pregnancy. , 160-164.
CrossRef188
Laura M. DiGiovanni. (2010) Ethical Issues in Obstetrics. Obstetrics and Gynecology Clinics of North America 37:2, 345-357
CrossRef189
S. Zhao, Y. Gu, R. Fan, L.J. Groome, D. Cooper, Y. Wang. (2010) Proteases and sFlt-1 Release in the Human Placenta. Placenta 31:6, 512-518
CrossRef190
Eva Meler, Francesc Figueras, Mar Bennasar, Olga Gomez, Fatima Crispi, Eduard Gratacos. (2010) The prognostic role of uterine artery Doppler investigation in patients with severe early-onset preeclampsia. American Journal of Obstetrics and Gynecology 202:6, 559.e1-559.e4
CrossRef191
Tinnakorn Chaiworapongsa, Roberto Romero, Adi L. Tarca, Juan Pedro Kusanovic, Francesca Gotsch, Pooja Mittal, Sun Kwon Kim, Edi Vaisbuch, Shali Mazaki-Tovi, Offer Erez, Zhong Dong, Chong Jai Kim, Lami Yeo, Sonia S. Hassan. (2010) A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. American Journal of Obstetrics and Gynecology 202:6, 550.e1-550.e10
CrossRef192
Asmita V Kulkarni, Savita S Mehendale, Hemlata R Yadav, Anitha S Kilari, Vaishali S Taralekar, Sadhana R Joshi. (2010) Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertension Research 33:6, 561-567
CrossRef193
Alexandre Hertig, Julie Fort, Guillaume Lefevre, Nathalie Chabbert-Buffet, Martine Uzan, Eric Rondeau, Patrick Rozenberg. (2010) Soluble endoglin in preeclamptic patients with or without HELLP syndrome. American Journal of Obstetrics and Gynecology 202:6, 594.e1-594.e4
CrossRef194
Michelle Silasi, Bruce Cohen, S. Ananth Karumanchi, Sarosh Rana. (2010) Abnormal Placentation, Angiogenic Factors, and the Pathogenesis of Preeclampsia. Obstetrics and Gynecology Clinics of North America 37:2, 239-253
CrossRef195
Michelle A. Josephson, Dianne B. McKay. (2010) Pregnancy in the Renal Transplant Recipient. Obstetrics and Gynecology Clinics of North America 37:2, 211-222
CrossRef196
François Audibert. (2010) Maternal serum screening for preeclampsia: Is performance enough?. Clinical Biochemistry 43:9, 707-708
CrossRef197
Silvana Litwin, María E. Cortina, Gabriela L. Barrientos, María B. Prados, María E. Roux, Silvia E. Miranda. (2010) Multiparity increases trophoblast invasion and vascular endothelial growth factor expression at the maternal–fetal interface in mice. Journal of Reproductive Immunology 85:2, 161-167
CrossRef198
Isabelle Ligi, Isabelle Grandvuillemin, Virginie Andres, Françoise Dignat-George, Umberto Simeoni. (2010) Low Birth Weight Infants and the Developmental Programming of Hypertension: A Focus on Vascular Factors. Seminars in Perinatology 34:3, 188-192
CrossRef199
Astrid Bergmann, Shakil Ahmad, Melissa Cudmore, Achim D. Gruber, Petra Wittschen, Werner Lindenmaier, Gerhard Christofori, Volkmar Gross, Andrey Ch. da Costa Gonzalves, Hermann-Josef Gröne, Asif Ahmed, Herbert A. Weich. (2010) Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. Journal of Cellular and Molecular Medicine 14:6b, 1857-1867
CrossRef200
J. Schiettecatte, H. Russcher, E. Anckaert, M. Mees, B. Leeser, A.S. Tirelli, G.M. Fiedler, H. Luthe, B. Denk, J. Smitz. (2010) Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clinical Biochemistry 43:9, 768-770
CrossRef201
Takeshi Nagamatsu, Danny J. Schust. (2010) The Contribution of Macrophages to Normal and Pathological Pregnancies. American Journal of Reproductive Immunology 63:6, 460-471
CrossRef202
Akihide Ohkuchi, Chikako Hirashima, Hirotada Suzuki, Kayo Takahashi, Mika Yoshida, Shigeki Matsubara, Mitsuaki Suzuki. (2010) Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertension Research 33:5, 422-427
CrossRef203
Kazuya Mimura, Takuji Tomimatsu, Namuxila Sharentuya, Ekaterine Tskitishvili, Yukiko Kinugasa-Taniguchi, Takeshi Kanagawa, Tadashi Kimura. (2010) Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia. American Journal of Obstetrics and Gynecology 202:5, 464.e1-464.e6
CrossRef204
Surendra Sharma, Wendy E. Norris, Satyan Kalkunte. (2010) Beyond the threshold: an etiological bridge between hypoxia and immunity in preeclampsia. Journal of Reproductive Immunology 85:1, 112-116
CrossRef205
Sindhu K. Srinivas, Alanna C. Morrison, Christina M. Andrela, Michal A. Elovitz. (2010) Allelic variations in angiogenic pathway genes are associated with preeclampsia. American Journal of Obstetrics and Gynecology 202:5, 445.e1-445.e11
CrossRef206
Hidetaka Okada, Akihiro Tsutsumi, Miyuki Imai, Tatsuya Nakajima, Katsuhiko Yasuda, Hideharu Kanzaki. (2010) Estrogen and selective estrogen receptor modulators regulate vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in human endometrial stromal cells. Fertility and Sterility 93:8, 2680-2686
CrossRef207
A Sekizawa, Y Purwosunu, A Farina, H Shimizu, M Nakamura, N Wibowo, N Rizzo, T Okai. (2010) Prediction of pre-eclampsia by an analysis of placenta-derived cellular mRNA in the blood of pregnant women at 15-20 weeks of gestation. BJOG: An International Journal of Obstetrics & Gynaecology 117:5, 557-564
CrossRef208
Anne R. Hansen, Carmen M. Barnés, Judah Folkman, Thomas F. McElrath. (2010) Maternal Preeclampsia Predicts the Development of Bronchopulmonary Dysplasia. The Journal of Pediatrics 156:4, 532-536
CrossRef209
T. Groten, N. Gebhard, R. Kreienberg, E. Schleußner, F. Reister, B. Huppertz. (2010) Differential expression of VE-cadherin and VEGFR2 in placental syncytiotrophoblast during preeclampsia – New perspectives to explain the pathophysiology. Placenta 31:4, 339-343
CrossRef210
AM Lynch, JR Murphy, RS Gibbs, RJ Levine, PC Giclas, JE Salmon, VM Holers. (2010) The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology 117:4, 456-462
CrossRef211
Elena Chinni, Donatella Colaizzo, Giovanni L. Tiscia, Pasquale Martinelli, Giuseppe M. Maruotti, Maria Matteo, Maurizio Margaglione, Elvira Grandone. (2010) Markers of haemostasis and angiogenesis in placentae from gestational vascular complications: Impairment of mechanisms involved in maintaining intervillous blood flow. Thrombosis Research 125:3, 267-271
CrossRef212
Guy Steinberg, Chulmin Lee, Jose Alejandro Rauh-Hain, Jeffrey Ecker, Eliyahu V. Khankin, Chaur-Dong Hsu, Bruce Cohen, Sarosh Rana, S. Ananth Karumanchi, Ravi Thadhani, Michele R. Hacker, Kee-Hak Lim. (2010) Early-pregnancy soluble Fas levels in idiopathic small-for-gestational-age pregnancies. American Journal of Obstetrics and Gynecology 202:3, 299.e1-299.e7
CrossRef213
T. Kasdaglis, G. Aberdeen, O. Turan, J. Kopelman, R. Atlas, C. Jenkins, M. Blitzer, C. Harman, A. A. Baschat. (2010) Placental growth factor in the first trimester: relationship with maternal factors and placental Doppler studies. Ultrasound in Obstetrics and Gynecology 35:3, 280-285
CrossRef214
Edi Vaisbuch, Roberto Romero, Shali Mazaki-Tovi, Offer Erez, Sun Kwon Kim, Tinnakorn Chaiworapongsa, Francesca Gotsch, Nandor Gabor Than, Zhong Dong, Percy Pacora, Ronald Lamont, Lami Yeo, Sonia S. Hassan, Juan Pedro Kusanovic. (2010) Retinol binding protein 4 – a novel association with early-onset preeclampsia. Journal of Perinatal Medicine 38:2, 129-139
CrossRef215
Robert J. Biggar, Gry Poulsen, Jennifer Ng, Mads Melbye, Heather A. Boyd. (2010) HLA antigen sharing between mother and fetus as a risk factor for eclampsia and preeclampsia. Human Immunology 71:3, 263-267
CrossRef216
M. Messerli, K. May, S.R. Hansson, H. Schneider, W. Holzgreve, S. Hahn, C. Rusterholz. (2010) Feto-maternal interactions in pregnancies: Placental microparticles activate peripheral blood monocytes. Placenta 31:2, 106-112
CrossRef217
Haruki Nishizawa, Takema Kato, Sayuri Ota, Sachie Nishiyama, Kanako Pryor-Koishi, Machiko Suzuki, Makiko Tsutsumi, Hidehito Inagaki, Hiroki Kurahashi, Yasuhiro Udagawa. (2010) Genetic Variation in the Indoleamine 2,3-Dioxygenase Gene in Pre-eclampsia. American Journal of Reproductive Immunology
CrossRef218
Yusuke Murakami, Yasuhiro Ikeda, Yoshikazu Yonemitsu, Masanori Miyazaki, Makoto Inoue, Mamoru Hasegawa, Katsuo Sueishi, Tatsuro Ishibashi. (2010) Inhibition of Choroidal Neovascularization via Brief Subretinal Exposure to a Newly Developed Lentiviral Vector Pseudotyped with Sendai Viral Envelope Proteins. Human Gene Therapy 21:2, 199-209
CrossRef219
David Kanter, Marshall D. Lindheimer, Eileen Wang, Romana G. Borromeo, Elizabeth Bousfield, S. Ananth Karumanchi, Isaac E. Stillman. (2010) Angiogenic dysfunction in molar pregnancy. American Journal of Obstetrics and Gynecology 202:2, 184.e1-184.e5
CrossRef220
T. Chaiworapongsa, R. Romero, J. P. Kusanovic, P. Mittal, S. K. Kim, F. Gotsch, N. G. Than, S. Mazaki-Tovi, E. Vaisbuch, O. Erez, L. Yeo, S. S. Hassan, Y. Sorokin. (2010) Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound in Obstetrics and Gynecology 35:2, 155-162
CrossRef221
Stefan Verlohren, Alberto Galindo, Dietmar Schlembach, Harald Zeisler, Ignacio Herraiz, Manfred G. Moertl, Juliane Pape, Joachim W. Dudenhausen, Barbara Denk, Holger Stepan. (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. American Journal of Obstetrics and Gynecology 202:2, 161.e1-161.e11
CrossRef222
H Masuyama, T Segawa, Y Sumida, A Masumoto, S Inoue, Y Akahori, Y Hiramatsu. (2010) Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology 117:3, 314-320
CrossRef223
CS Buhimschi, MA Baumbusch, AT Dulay, S Lee, M Wehrum, G Zhao, MO Bahtiyar, CM Pettker, UA Ali, EF Funai, IA Buhimschi. (2010) The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio. BJOG: An International Journal of Obstetrics & Gynaecology 117:3, 321-330
CrossRef224
Hiromichi Wada, Noriko Satoh, Shuji Kitaoka, Koh Ono, Tatsuya Morimoto, Teruhisa Kawamura, Tameo Nakano, Masatoshi Fujita, Toru Kita, Akira Shimatsu, Koji Hasegawa. (2010) Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis 208:2, 512-517
CrossRef225
Suseela Yelumalai, Sekaran Muniandy, Siti Zawiah Omar, Rajes Qvist. (2010) Pregnancy-Induced Hypertension and Preeclampsia: Levels of Angiogenic Factors in Malaysian Women. Journal of Clinical Biochemistry and Nutrition 47:3, 191-197
CrossRef226
Brett C. Young, Richard J. Levine, S. Ananth Karumanchi. (2010) Pathogenesis of Preeclampsia. Annual Review of Pathology: Mechanisms of Disease 5:1, 173-192
CrossRef227
Shin Young Kim, So Yeon Park, Jin Woo Kim, Mi Bum Lee, You Jung Han, Hyun Kyong Ahn, Jun Seek Choi, Jung Yeol Han, Moon Young Kim, Kyu Hong Choi, Hyun Mee Ryu. (2010) Reduced Number of Endothelial Progenitor Colony-Forming Units in Patients with Preeclampsia. Journal of Genetic Medicine 7:2, 138
CrossRef228
James S. McKinney, Steven R. Messé, Bryan A. Pukenas, Sudhakar R. Satti, John B. Weigele, Robert W. Hurst, Joshua M. Levine, Scott E. Kasner, Lauren H. Sansing. (2010) Intracranial Vertebrobasilar Artery Dissection Associated with Postpartum Angiopathy. Stroke Research and Treatment 2010, 1-5
CrossRef229
Ranjit Akolekar, Jader de Cruz, Jean-Michel Foidart, Carine Munaut, Kypros H. Nicolaides. (2010) Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenatal Diagnosisn/a-n/a
CrossRef230
Shiraz Sunderji, Emanuel Gaziano, Donald Wothe, Linda C. Rogers, Baha Sibai, S. Ananth Karumanchi, Cheryl Hodges-Savola. (2010) Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. American Journal of Obstetrics and Gynecology 202:1, 40.e1-40.e7
CrossRef231
Jaume Alijotas-Reig, Miquel Vilardell-Tarres. (2010) Is Obstetric Antiphospholipid Syndrome a Primary Nonthrombotic, Proinflammatory, Complement-Mediated Disorder Related to Antiphospholipid Antibodies?. Obstetrical & Gynecological Survey 65:1, 39-45
CrossRef232
Satyan Kalkunte, Zhongbin Lai, Wendy E. Norris, Linda A. Pietras, Neetu Tewari, Roland Boij, Stefan Neubeck, Udo R. Markert, Surendra Sharma. (2009) Novel approaches for mechanistic understanding and predicting preeclampsia. Journal of Reproductive Immunology 83:1-2, 134-138
CrossRef233
Geralyn M. Lambert-Messerlian, Glenn E. Palomaki, Louis M. Neveux, Edward Chien, Alex Friedman, Karen Rosene-Montella, Meghan Hayes, Jacob A. Canick. (2009) Early onset preeclampsia and second trimester serum markers. Prenatal Diagnosis 29:12, 1109-1117
CrossRef234
Anna-Karin Wikström, Peppi Nash, Ulf J. Eriksson, Matts H. Olovsson. (2009) Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia. American Journal of Obstetrics and Gynecology 201:6, 597.e1-597.e8
CrossRef235
Anne Eskild, Pål R. Romundstad, Lars J. Vatten. (2009) Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia?. American Journal of Obstetrics and Gynecology 201:6, 595.e1-595.e5
CrossRef236
Susana M. Campos, Benjamin D. Humphreys. (2009) Safety of Bevacizumab in Advanced Ovarian and Müllerian Cancers: A Review. Clinical Cancer Reviews 3:1, E7-E13
CrossRef237
I. Herraiz, J. Arbués, I. Camaño, E. Gómez-Montes, A. Grañeras, A. Galindo. (2009) Application of a first-trimester prediction model for pre-eclampsia based on uterine arteries and maternal history in high-risk pregnancies. Prenatal Diagnosis 29:12, 1123-1129
CrossRef238
Shahzya S Huda, Dilys J Freeman, Scott M Nelson. (2009) Short- and long-term strategies for the management of hypertensive disorders of pregnancy. Expert Review of Cardiovascular Therapy 7:12, 1581-1594
CrossRef239
Xin Zeng, Yu Sun, Hui-xia Yang, Dong Li, Yu-xia Li, Qin-ping Liao, Yan-ling Wang. (2009) Plasma level of soluble c-Met is tightly associated with the clinical risk of preeclampsia. American Journal of Obstetrics and Gynecology 201:6, 618.e1-618.e7
CrossRef240
Michelle A. Hladunewich, Guy Steinberg, S. Ananth Karumanchi, Richard J. Levine, Sarah Keating, John Kingdom, Johannes Keunen. (2009) Angiogenic factor abnormalities and fetal demise in a twin pregnancy. Nature Reviews Nephrology 5:11, 658-662
CrossRef241
Antonio Farina, Danila Morano, Diego Arcelli, Paola De Sanctis, Akihiko Sekizawa, Yuditiya Purwosunu, Cinzia Zucchini, Giuliana Simonazzi, Takashi Okai, Nicola Rizzo. (2009) Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening. Prenatal Diagnosis 29:11, 1038-1044
CrossRef242
Koji Matsuo, Andrew M. Malinow, Chris R. Harman, Ahmet A. Baschat. (2009) Decreased placental oxygenation capacity in pre-eclampsia: clinical application of a novel index of placental function preformed at the time of delivery. Journal of Perinatal Medicine 37:6, 657-661
CrossRef243
David F. Lewis, Bernard J. Canzoneri, Yuping Wang. (2009) ORIGINAL ARTICLE: Maternal Circulating TNF-α Levels are Highly Correlated with IL-10 Levels, but not IL-6 and IL-8 Levels, in Women with Pre-Eclampsia. American Journal of Reproductive Immunology 62:5, 269-274
CrossRef244
M.B. Franz, P.W. Husslein, H. Zeisler. (2009) Neue Methoden zur Früherkennung der Präeklampsie. Der Gynäkologe 42:11, 872-876
CrossRef245
Anna B. Katz, Sundeep G. Keswani, Mounira Habli, Foong Y. Lim, Philip W. Zoltick, Paola Midrio, Elliot D. Kozin, Meenhard Herlyn, Timothy M. Crombleholme. (2009) Placental gene transfer: transgene screening in mice for trophic effects on the placenta. American Journal of Obstetrics and Gynecology 201:5, 499.e1-499.e8
CrossRef246
Hairong Xu, Bryna Shatenstein, Zhong-Cheng Luo, Shuqin Wei, William Fraser. (2009) Role of nutrition in the risk of preeclampsia. Nutrition Reviews 67:11, 639-657
CrossRef247
Debra Goldman-Wohl, Simcha Yagel. (2009) Preeclampsia—a placenta developmental biology perspective. Journal of Reproductive Immunology 82:2, 96-99
CrossRef248
Marco Scioscia, Khalid Gumaa, Thomas W. Rademacher. (2009) The link between insulin resistance and preeclampsia: new perspectives. Journal of Reproductive Immunology 82:2, 100-105
CrossRef249
Phyllis Wachsberger, Randy Burd, Anderson Ryan, Constantine Daskalakis, Adam P. Dicker. (2009) Combination of Vandetanib, Radiotherapy, and Irinotecan in the LoVo Human Colorectal Cancer Xenograft Model. International Journal of Radiation Oncology*Biology*Physics 75:3, 854-861
CrossRef250
H. Zhao, R.J. Wong, F.S. Kalish, N.R. Nayak, D.K. Stevenson. (2009) Effect of Heme Oxygenase-1 Deficiency on Placental Development. Placenta 30:10, 861-868
CrossRef251
Vishna D. Nadarajah, Richard G. L. Y. Min, John P. Judson, Ravindran Jegasothy, Elena H. P. Ling. (2009) Maternal plasma soluble fms-like tyrosine kinase-1 and placental growth factor levels as biochemical markers of gestational hypertension for Malaysian mothers. Journal of Obstetrics and Gynaecology Research 35:5, 855-863
CrossRef252
Dirk Matthias Hermann, Anil Zechariah. (2009) Implications of vascular endothelial growth factor for postischemic neurovascular remodeling. Journal of Cerebral Blood Flow & Metabolism 29:10, 1620-1643
CrossRef253
Keizo Kanasaki, Raghu Kalluri. (2009) The biology of preeclampsia. Kidney International 76:8, 831-837
CrossRef254
R.M. Gobble, K.A. Groesch, M. Chang, R.J. Torry, D.S. Torry. (2009) Differential Regulation of Human PlGF Gene Expression in Trophoblast and Nontrophoblast Cells by Oxygen Tension. Placenta 30:10, 869-875
CrossRef255
Pardeep Kumar Aggarwal, Vanita Jain, Radhika Srinivasan, Vivekanand Jha. (2009) Maternal EDN1 G5665T polymorphism influences circulating endothelin-1 levels and plays a role in determination of preeclampsia phenotype. Journal of Hypertension 27:10, 2044-2050
CrossRef256
Simcha Yagel. (2009) The developmental role of natural killer cells at the fetal-maternal interface. American Journal of Obstetrics and Gynecology 201:4, 344-350
CrossRef257
Ranjit Akolekar, Davide Casagrandi, Evdoxia Skyfta, Abubaker Abdalla Ahmed, Kypros H. Nicolaides. (2009) Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis 29:9, 847-851
CrossRef258
Carol Lin, Augustine Rajakumar, Daniel A. Plymire, Vivek Verma, Nina Markovic, Carl A. Hubel. (2009) Maternal Endothelial Progenitor Colony-Forming Units With Macrophage Characteristics Are Reduced in Preeclampsia. American Journal of Hypertension 22:9, 1014-1019
CrossRef259
Raymond C.S. Seet, Adeline W.L. Chow, Amy M.L. Quek, Yiong-Huak Chan, Erle C.H. Lim. (2009) Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case–control study. International Journal of Infectious Diseases 13:5, e248-e253
CrossRef260
Amanda L. Horton, Kim A. Boggess, Kevin L. Moss, James Beck, Steven Offenbacher. (2009) Maternal Periodontal Disease and Soluble Fms-Like Tyrosine Kinase-1 Expression. Journal of Periodontology 80:9, 1506-1510
CrossRef261
E. Nakada, K.R. Walley, T. Nakada, Y. Hu, P. von Dadelszen, J.H. Boyd. (2009) Toll-like Receptor-3 Stimulation Upregulates sFLT-1 Production by Trophoblast Cells. Placenta 30:9, 774-779
CrossRef262
Hamid Reza Nakhai-Pour, Evelyne Rey, Anick Bérard. (2009) Discontinuation of antihypertensive drug use during the first trimester of pregnancy and the risk of preeclampsia and eclampsia among women with chronic hypertension. American Journal of Obstetrics and Gynecology 201:2, 180.e1-180.e8
CrossRef263
Jimmy Espinoza, John E. Uckele, Robert A. Starr, Robert P. Lorenz, Richard A. Bronsteen, Stanley M. Berry. (2009) Insights Into Angiogenic Imbalances During Pregnancy. Obstetrics & Gynecology 114:Supplement, 437-440
CrossRef264
B Xu, C Thornton, J Tooher, R Ogle, S Lim, A Makris, A Hennessy. (2009) EFFECTS OF ANTI-HYPERTENSIVE DRUGS ON PRODUCTION OF SOLUBLE FMS-LIKE TYROSINE KINASE 1 AND SOLUBLE ENDOGLIN FROM HUMAN NORMAL AND PRE-ECLAMPTIC PLACENTAS IN VITRO. Clinical and Experimental Pharmacology and Physiology 36:8, 839-842
CrossRef265
Marie Bolin, Eva Wiberg-Itzel, Anna-Karin Wikström, Margareta Goop, Anders Larsson, Matts Olovsson, Helena Åkerud. (2009) Angiopoietin-1/Angiopoietin-2 Ratio for Prediction of Preeclampsia. American Journal of Hypertension 22:8, 891-895
CrossRef266
T. F. McElrath, J. L. Hecht. (2009) Invited Commentary: Intrauterine Epidemiology. American Journal of Epidemiology 170:2, 159-161
CrossRef267
R. Kelly, C. Holzman, P. Senagore, J. Wang, Y. Tian, M. H. Rahbar, H. Chung. (2009) Placental Vascular Pathology Findings and Pathways to Preterm Delivery. American Journal of Epidemiology 170:2, 148-158
CrossRef268
Yan-Qiong Ouyang, Si-Jian Li, Qing Zhang, Wen-Pei Xiang, Hong-Ling Shen, Han-Ping Chen, Hong Chen, Hui-Zhen Chen. (2009) Plasma sFlt-1-to-PlGF ratio is correlated with inflammatory but not with oxidative stress in Chinese preeclamptic women. Archives of Gynecology and Obstetrics 280:1, 91-97
CrossRef269
Katherine W Arendt, Vesna D Garovic. (2009) Association of deficiencies of catechol- O -methyltransferase and 2-methoxyestradiol with preeclampsia. Expert Review of Obstetrics & Gynecology 4:4, 379-381
CrossRef270
Shali Mazaki-Tovi, Roberto Romero, Edi Vaisbuch, Juan Pedro Kusanovic, Offer Erez, Francesca Gotsch, Tinnakorn Chaiworapongsa, Nandor Gabor Than, Sun Kwon Kim, Chia-Ling Nhan-Chang, Cristiano Jodicke, Percy Pacora, Lami Yeo, Zhong Dong, Bo Hyun Yoon, Sonia S. Hassan, Pooja Mittal. (2009) Maternal serum adiponectin multimers in preeclampsia. Journal of Perinatal Medicine 37:4, 349-363
CrossRef271
Masamitsu Nakamura, Akihiko Sekizawa, Yuditiya Purwosunu, Shiho Okazaki, Antonio Farina, Noroyono Wibowo, Hanako Shimizu, Takashi Okai. (2009) Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenatal Diagnosis 29:7, 691-696
CrossRef272
Hugo R. Arias, Victoria E. Richards, David Ng, Mary E. Ghafoori, Vanique Le, Shaker A. Mousa. (2009) Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. The International Journal of Biochemistry & Cell Biology 41:7, 1441-1451
CrossRef273
Neil J. Perkins, Enrique F. Schisterman, Albert Vexler. (2009) Generalized ROC curve inference for a biomarker subject to a limit of detection and measurement error. Statistics in Medicine 28:13, 1841-1860
CrossRef274
Anne Vambergue. (2009) Facteurs anti-angiogéniques et prééclampsie au cours de la grossesse diabétique de type 1. Diabetologia Notes de lecture 1:1, 9-10
CrossRef275
Marion Blumenstein, Michael T. McMaster, Michael A. Black, Steven Wu, Roneel Prakash, Janine Cooney, Lesley M. E. McCowan, Garth J. S. Cooper, Robyn A. North. (2009) A proteomic approach identifies early pregnancy biomarkers for preeclampsia: Novel linkages between a predisposition to preeclampsia and cardiovascular disease. PROTEOMICS 9:11, 2929-2945
CrossRef276
Jason P. Bridges, Jeffrey S. Gilbert, Drew Colson, Sara A. Gilbert, Matthew P. Dukes, Michael J. Ryan, Joey P. Granger. (2009) Oxidative Stress Contributes to Soluble Fms-Like Tyrosine Kinase-1 Induced Vascular Dysfunction in Pregnant Rats. American Journal of Hypertension 22:5, 564-568
CrossRef277
Anne Gingery, Emma L Bahe, Jeffrey S Gilbert. (2009) Placental ischemia and breast cancer risk after preeclampsia: tying the knot. Expert Review of Anticancer Therapy 9:5, 671-681
CrossRef278
Baha M. Sibai, Caroline L. Stella. (2009) Diagnosis and management of atypical preeclampsia-eclampsia. American Journal of Obstetrics and Gynecology 200:5, 481.e1-481.e7
CrossRef279
Young Nam Kim, Dae Shim Lee, Dae Hoon Jeong, Moon Su Sung, Ki Tae Kim. (2009) The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenatal Diagnosis 29:5, 464-470
CrossRef280
Christina M. Scifres, Jay D. Iams, Mark Klebanoff, George A. Macones. (2009) Metaanalysis vs large clinical trials: which should guide our management?. American Journal of Obstetrics and Gynecology 200:5, 484.e1-484.e5
CrossRef281
P. Redecha, N. van Rooijen, D. Torry, G. Girardi. (2009) Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 113:17, 4101-4109
CrossRef282
Benjamin D. Byers, Ancizar Betancourt, Fangxian Lu, Gary D.V. Hankins, Monica Longo, George R. Saade, Egle Bytautiene. (2009) The effect of prepregnancy obesity and sFlt-1–induced preeclampsia-like syndrome on fetal programming of adult vascular function in a mouse model. American Journal of Obstetrics and Gynecology 200:4, 432.e1-432.e7
CrossRef283
Marja Lohela, Maija Bry, Tuomas Tammela, Kari Alitalo. (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Current Opinion in Cell Biology 21:2, 154-165
CrossRef284
Marek Jankowski. (2009) Angiogenesis inhibition and preeclampsia. Journal of Hypertension 27:4, 707-708
CrossRef285
MD Savvidou, R Akolekar, E Zaragoza, LC Poon, KH Nicolaides. (2009) First trimester urinary placental growth factor and development of pre-eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology 116:5, 643-647
CrossRef286
Yuditiya Purwosunu, Akihiko Sekizawa, Shiho Okazaki, Antonio Farina, Noroyono Wibowo, Masamitsu Nakamura, Nicola Rizzo, Hiroshi Saito, Takashi Okai. (2009) Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. American Journal of Obstetrics and Gynecology 200:4, 386.e1-386.e7
CrossRef287
Alexander M. Holston, Cong Qian, Kai F. Yu, Franklin H. Epstein, S. Ananth Karumanchi, Richard J. Levine. (2009) Circulating angiogenic factors in gestational proteinuria without hypertension. American Journal of Obstetrics and Gynecology 200:4, 392.e1-392.e10
CrossRef288
Elaine Unemori, Baha Sibai, Sam L Teichman. (2009) Scientific Rationale and Design of a Phase I Safety Study of Relaxin in Women with Severe Preeclampsia. Annals of the New York Academy of Sciences 1160:1, 381-384
CrossRef289
Gordon CS Smith, Helen Wear. (2009) The perinatal implications of angiogenic factors. Current Opinion in Obstetrics and Gynecology 21:2, 111-116
CrossRef290
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Singhal, Aneesh B., Kimberly, W. Taylor, Schaefer, Pamela W., Hedley-Whyte, E. Tessa, . (2009) Case 8-2009. New England Journal of Medicine 360:11, 1126-1137
Full Text291
L. MYATT, R. P. WEBSTER. (2009) Vascular biology of preeclampsia. Journal of Thrombosis and Haemostasis 7:3, 375-384
CrossRef292
Holger Stepan, Thomas Ebert, Susanne Schrey, Constanze Reisenbüchler, Sebastian Stein, Ulrike Lossner, Matthias Bluher, Michael Stumvoll, Jürgen Kratzsch, Renaldo Faber, Mathias Fasshauer. (2009) Serum Levels of Angiopoietin-Related Growth Factor Are Increased in Preeclampsia. American Journal of Hypertension 22:3, 314-318
CrossRef293
T. Cindrova-Davies. (2009) Gabor Than Award Lecture 2008: Pre-eclampsia – From Placental Oxidative Stress to Maternal Endothelial Dysfunction. Placenta 30, 55-65
CrossRef294
Alan L. Schwartz, Aaron Ciechanover. (2009) Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology. Annual Review of Pharmacology and Toxicology 49:1, 73-96
CrossRef295
AA Khalil, DJ Cooper, KF Harrington. (2009) Pulse wave analysis: a preliminary study of a novel technique for the prediction of pre-eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology 116:2, 268-277
CrossRef296
Y. Yu, A. J. Jenkins, A. J. Nankervis, K. F. Hanssen, H. Scholz, T. Henriksen, B. Lorentzen, T. Clausen, S. K. Garg, M. K. Menard, S. M. Hammad, J. C. Scardo, J. R. Stanley, A. Dashti, K. May, K. Lu, C. E. Aston, J. J. Wang, S. X. Zhang, J.-X. Ma, T. J. Lyons. (2009) Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia 52:1, 160-168
CrossRef297
O. Pourrat, F. Pierre, G. Magnin. (2009) Le syndrome HELLP : les dix commandements. La Revue de Médecine Interne 30:1, 58-64
CrossRef298
Peter V Hauser, Federica Collino, Benedetta Bussolati, Giovanni Camussi. (2009) Nephrin and endothelial injury. Current Opinion in Nephrology and Hypertension 18:1, 3-8
CrossRef299
A. Rajakumar, R.W. Powers, C.A. Hubel, E. Shibata, F. von Versen-Höynck, D. Plymire, A. Jeyabalan. (2009) Novel Soluble Flt-1 Isoforms in Plasma and Cultured Placental Explants from Normotensive Pregnant and Preeclamptic Women. Placenta 30:1, 25-34
CrossRef300
Guy Steinberg, Eliyahu V. Khankin, S. Ananth Karumanchi. (2009) Angiogenic factors and preeclampsia. Thrombosis Research 123, S93-S99
CrossRef301
Stephen F. Thung, Errol R. Norwitz. 2009. Endocrine Diseases of Pregnancy. , 615-658.
CrossRef302
V. Tsatsaris, T. Fournier, N. Winer. 2009. Physiopathologie de la prééclampsie. , 22-33.
CrossRef303
F. Bretelle, R. Ledu, J.-B. Haumonté, R. Shojai, C. d'Ercole, L. Boubli. 2009. Comment prédire la prééclampsie?. , 34-46.
CrossRef304
Chun Lam, S. Ananth Karumanchi. 2009. Pregnancy and the Kidney. , 483-513.
CrossRef305
Robert N. Taylor, Sandra T. Davidge, James M. Roberts. 2009. Endothelial Cell Dysfunction and Oxidative Stress. , 143-167.
CrossRef306
S. Ananth Karumanchi, Isaac E. Stillman, Marshall D. Lindheimer. 2009. Angiogenesis and Preeclampsia. , 87-103.
CrossRef307
Judith U. Hibbard, Sanjeev G. Shroff, Marshall D. Lindheimer. 2009. Cardiovascular Alterations in Normal and Preeclamptic Pregnancy. , 249-267.
CrossRef308
Roberta B. Ness, James M. Roberts. 2009. Epidemiology of Pregnancy-Related Hypertension. , 37-50.
CrossRef309
F. Fakhouri, M. Jablonski, J. Lepercq, J. Blouin, A. Benachi, M. Hourmant, Y. Pirson, A. Durrbach, J.-P. Grunfeld, B. Knebelmann, V. Fremeaux-Bacchi. (2008) Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 112:12, 4542-4545
CrossRef310
Rebecca Troisi, Kristin Braekke, Nina Kittelsen Harsem, Marianne Hyer, Robert N. Hoover, Anne Cathrine Staff. (2008) Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. American Journal of Obstetrics and Gynecology 199:6, 653.e1-653.e10
CrossRef311
Ugo Testa, Gaetano Pannitteri, Gian Luigi Condorelli. (2008) Vascular endothelial growth factors in cardiovascular medicine. Journal of Cardiovascular Medicine 9:12, 1190-1221
CrossRef312
M. D. Savvidou, M. Noori, J. M. Anderson, A. D. Hingorani, K. H. Nicolaides. (2008) Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound in Obstetrics and Gynecology 32:7, 871-876
CrossRef313
M Barry Stokes, Maria C Erazo, Vivette D D'Agati. (2008) Glomerular disease related to anti-VEGF therapy. Kidney International 74:11, 1487-1491
CrossRef314
Erica P. Gunderson, Vicky Chiang, Cora E. Lewis, Janet Catov, Charles P. Quesenberry, Stephen Sidney, Gina S. Wei, Roberta Ness. (2008) Long-Term Blood Pressure Changes Measured From Before to After Pregnancy Relative to Nonparous Women. Obstetrics & Gynecology 112:6, 1294-1302
CrossRef315
G. Bollee, N. Patey, G. Cazajous, C. Robert, J.-M. Goujon, F. Fakhouri, P. Bruneval, L.-H. Noel, B. Knebelmann. (2008) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrology Dialysis Transplantation 24:2, 682-685
CrossRef316
Ralf Dechend, Friedrich C. Luft. (2008) Are we getting closer to a Nobel Prize for unraveling preeclampsia?. Current Cardiology Reports 10:6, 440-447
CrossRef317
P. Brownbill, T.A. Mills, D.F. Soydemir, C.P. Sibley. (2008) Vasoactivity to and Endogenous Release of Vascular Endothelial Growth Factor in the in vitro Perfused Human Placental Lobule from Pregnancies Complicated by Preeclampsia. Placenta 29:11, 950-955
CrossRef318
Celia J. Fang, Anna Richards, M. Kathryn Liszewski, David Kavanagh, John P. Atkinson. (2008) Advances in understanding of pathogenesis of aHUS and HELLP. British Journal of Haematology 143:3, 336-348
CrossRef319
Ralf Dechend, Friedrich C Luft. (2008) Angiogenesis factors and preeclampsia. Nature Medicine 14:11, 1187-1188
CrossRef320
Magnus Centlow, Piero Carninci, Krisztian Nemeth, Eva Mezey, Michael Brownstein, Stefan R. Hansson. (2008) Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. Fertility and Sterility 90:5, 1834-1843
CrossRef321
R Gonen, R Shahar, YI Grimpel, I Chefetz, M Sammar, H Meiri, Y Gibor. (2008) Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG: An International Journal of Obstetrics & Gynaecology 115:12, 1465-1472
CrossRef322
R. Akolekar, E. Zaragoza, L. C. Y. Poon, S. Pepes, K. H. Nicolaides. (2008) Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound in Obstetrics and Gynecology 32:6, 732-739
CrossRef323
Jeffrey S Gilbert, Mark J Nijland, Penny Knoblich. (2008) Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Review of Cardiovascular Therapy 6:10, 1367-1377
CrossRef324
Jennifer Williams, Ellen Mozurkewich, Julie Chilimigras, Cosmas Van De Ven. (2008) Critical care in obstetrics: pregnancy-specific conditions. Best Practice & Research Clinical Obstetrics & Gynaecology 22:5, 825-846
CrossRef325
S. Kalkunte, Z. Lai, N. Tewari, C. Chichester, R. Romero, J. Padbury, S. Sharma. (2008) In Vitro and In Vivo Evidence for Lack of Endovascular Remodeling by Third Trimester Trophoblasts. Placenta 29:10, 871-878
CrossRef326
Nachman, Ralph L., Rafii, Shahin, . (2008) Platelets, Petechiae, and Preservation of the Vascular Wall. New England Journal of Medicine 359:12, 1261-1270
Full Text327
A. Muehlenbachs, M. Fried, J. Lachowitzer, T. K. Mutabingwa, P. E. Duffy. (2008) From the Cover: Natural selection of FLT1 alleles and their association with malaria resistance in utero. Proceedings of the National Academy of Sciences 105:38, 14488-14491
CrossRef328
S. A. Karumanchi, D. Haig. (2008) Flt1, pregnancy, and malaria: Evolution of a complex interaction. Proceedings of the National Academy of Sciences 105:38, 14243-14244
CrossRef329
R.A. Irani, Y. Xia. (2008) The Functional Role of the Renin–Angiotensin System in Pregnancy and Preeclampsia. Placenta 29:9, 763-771
CrossRef330
Alexandre Hertig, Suzanne Watnick, Helena Strevens, Henri Boulanger, Nadia Berkane, Eric Rondeau. (2008) How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nature Clinical Practice Nephrology 4:9, 503-509
CrossRef331
Baha M. Sibai, Matthew A. Koch, Salvio Freire, Joao Luiz Pinto e Silva, Marilza Vieira Cunha Rudge, Sérgio Martins-Costa, Janet Bartz, Cleide de Barros Santos, Jose Guilherme Cecatti, Roberto Costa, José Geraldo Ramos, Joseph A. Spinnato. (2008) Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia?. American Journal of Obstetrics and Gynecology 199:3, 268.e1-268.e9
CrossRef332
Caroline Signore, James L. Mills, Cong Qian, Kai F. Yu, Sarosh Rana, S. Ananth Karumanchi, Richard J. Levine. (2008) Circulating soluble endoglin and placental abruption. Prenatal Diagnosis 28:9, 852-858
CrossRef333
ARVIND GUPTA, SUBASHINI KALIAPERUMAL, SAJITA SETIA, SMITHA T. SUCHI, VASUDEV ANAND RAO. (2008) RETINOPATHY IN PREECLAMPSIA. Retina 28:8, 1104-1110
CrossRef334
Marc U. Baumann, Nick A. Bersinger, Markus G. Mohaupt, Luigi Raio, Susan Gerber, Daniel V. Surbek. (2008) First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. American Journal of Obstetrics and Gynecology 199:3, 266.e1-266.e6
CrossRef335
Vikse, Bjørn Egil, Irgens, Lorentz M., Leivestad, Torbjørn, Skjærven, Rolv, Iversen, Bjarne M., . (2008) Preeclampsia and the Risk of End-Stage Renal Disease. New England Journal of Medicine 359:8, 800-809
Full Text336
H. Nishizawa, K. Pryor-Koishi, M. Suzuki, T. Kato, H. Kogo, T. Sekiya, H. Kurahashi, Y. Udagawa. (2008) Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients. Molecular Human Reproduction 14:10, 595-602
CrossRef337
D. Dragun, A. Haase-Fielitz. (2008) Low catechol-O-methyltransferase and 2-methoxyestradiol in preeclampsia: more than a unifying hypothesis. Nephrology Dialysis Transplantation 24:1, 31-33
CrossRef338
D.S. Tannetta, I.L. Sargent, E.A. Linton, C.W.G. Redman. (2008) Vitamins C and E Inhibit Apoptosis of Cultured Human Term Placenta Trophoblast. Placenta 29:8, 680-690
CrossRef339
Abdalla E. Diab, Manal M. El-Behery, Moustafa A. Ebrahiem, Amal E. Shehata. (2008) Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. International Journal of Gynecology & Obstetrics 102:2, 146-151
CrossRef340
John R. Barton, Baha M. Sibai. (2008) Prediction and Prevention of Recurrent Preeclampsia. Obstetrics & Gynecology 112:2, Part 1, 359-372
CrossRef341
Cissy C Zhou, Yujin Zhang, Roxanna A Irani, Hong Zhang, Tiejuan Mi, Edwina J Popek, M John Hicks, Susan M Ramin, Rodney E Kellems, Yang Xia. (2008) Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nature Medicine 14:8, 855-862
CrossRef342
Yu-Ting Chang, Ming-Chu Chang, Shu-Chen Wei, Yu-Wen Tien, Chiun Hsu, Po-Chin Liang, Po-Nien Tsao, I-Shiow Jan, Jau-Min Wong. (2008) Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer. Pancreas 37:2, 145-150
CrossRef343
Arun Jeyabalan, Robert W. Powers, Allison R. Durica, Gail F. Harger, James M. Roberts, Roberta B. Ness. (2008) Cigarette Smoke Exposure and Angiogenic Factors in Pregnancy and Preeclampsia. American Journal of Hypertension 21:8, 943-947
CrossRef344
M. J. Telen. (2008) It really IS the red cell. Blood 112:3, 459-460
CrossRef345
Roberto Romero, Juan Pedro Kusanovic, Nandor Gabor Than, Offer Erez, Francesca Gotsch, Jimmy Espinoza, Samuel Edwin, Ilana Chefetz, Ricardo Gomez, Jyh Kae Nien, Marei Sammar, Beth Pineles, Sonia S. Hassan, Hamutal Meiri, Yossi Tal, Ido Kuhnreich, Zoltan Papp, Howard S. Cuckle. (2008) First-trimester maternal serum PP13 in the risk assessment for preeclampsia. American Journal of Obstetrics and Gynecology 199:2, 122.e1-122.e11
CrossRef346
Azim Nejatizadeh, Tsering Stobdan, Neena Malhotra, M. A. Qadar Pasha. (2008) The Genetic Aspects of Pre-eclampsia: Achievements and Limitations. Biochemical Genetics 46:7-8, 451-479
CrossRef347
Jian-Wei Gu, Amelia P. Bailey, Wei Tan, Megan Shparago, Emily Young. (2008) Long-term high-salt diet causes hypertension and decreases renal expression of vascular endothelial growth factor in Sprague-Dawley rats. Journal of the American Society of Hypertension 2:4, 275-285
CrossRef348
Keizo Kanasaki, Kristin Palmsten, Hikaru Sugimoto, Shakil Ahmad, Yuki Hamano, Liang Xie, Samuel Parry, Hellmut G. Augustin, Vincent H. Gattone, Judah Folkman, Jerome F. Strauss, Raghu Kalluri. (2008) Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 453:7198, 1117-1121
CrossRef349
E. Curiel, M.A. Prieto, J. Mora. (2008) Factores relacionados con el desarrollo de preeclampsia. Revisión de la bibliografía. Clínica e Investigación en Ginecología y Obstetricia 35:3, 87-97
CrossRef350
Ji Hyae Lim, Shin Young Kim, So Yeon Park, Jae Hyug Yang, Moon Young Kim, Hyun Mee Ryu. (2008) Effective Prediction of Preeclampsia by a Combined Ratio of Angiogenesis-Related Factors. Obstetrics & Gynecology 111:6, 1403-1409
CrossRef351
Hui Yi Shan, Sarosh Rana, Franklin H. Epstein, Isaac E. Stillman, S. Ananth Karumanchi, Mark E. Williams. (2008) Use of Circulating Antiangiogenic Factors to Differentiate Other Hypertensive Disorders From Preeclampsia in a Pregnant Woman on Dialysis. American Journal of Kidney Diseases 51:6, 1029-1032
CrossRef352
Marzena Laskowska, Bożena Leszczyńska-Gorzelak, Katarzyna Laskowska, Jan Oleszczuk. (2008) Analysis of the sFlt-1 in pregnancies complicated by preeclampsia with and without IUGR. Annales UMCS, Medicina 63:1, 148-154
CrossRef353
Florian Herse, Anne Cathrine Staff, Lydia Hering, Dominik N. Müller, Friedrich C. Luft, Ralf Dechend. (2008) AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. Journal of Molecular Medicine 86:6, 697-703
CrossRef354
Ramsi Haddad, Roberto Romero, Barbara R. Gould, Gerard Tromp, Francesca Gotsch, Samuel S. Edwin, Hans H. Zingg. (2008) Angiogenesis gene expression in mouse uterus during the common pathway of parturition. American Journal of Obstetrics and Gynecology 198:5, 539.e1-539.e8
CrossRef355
V.Y. Gu, M.H. Wong, J.L. Stevenson, K.E. Crawford, S.P. Brennecke, N.M. Gude. (2008) Calreticulin in human pregnancy and pre-eclampsia. Molecular Human Reproduction 14:5, 309-315
CrossRef356
Masabumi Shibuya. (2008) Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Reports 41:4, 278-286
CrossRef357
Gilbert, Richard E., Marsden, Philip A., . (2008) Activated Protein C and Diabetic Nephropathy. New England Journal of Medicine 358:15, 1628-1630
Full Text358
Nathan I. Shapiro, Kiichiro Yano, Hitomi Okada, Christopher Fischer, Michael Howell, Katherine C. Spokes, Long Ngo, Derek C. Angus, William C. Aird. (2008) A PROSPECTIVE, OBSERVATIONAL STUDY OF SOLUBLE FLT-1 AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN SEPSIS. Shock 29:4, 452-457
CrossRef359
Yuval Bdolah, Chun Lam, Augustine Rajakumar, Venkatesha Shivalingappa, Walter Mutter, Benjamin P. Sachs, Kee Hak Lim, Tali Bdolah-Abram, Franklin H. Epstein, S. Ananth Karumanchi. (2008) Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?. American Journal of Obstetrics and Gynecology 198:4, 428.e1-428.e6
CrossRef360
Joan S Hunt, Margaret G Petroff. 2008. Molecular immunology of the maternal–fetal interface. , 524-545.
CrossRef361
Juan Pedro Kusanovic, Roberto Romero, Jimmy Espinoza, Jyh Kae Nien, Chong Jai Kim, Pooja Mittal, Sam Edwin, Offer Erez, Francesca Gotsch, Shali Mazaki-Tovi, Nandor G. Than, Eleazar Soto, Natalia Camacho, Ricardo Gomez, Ruben Quintero, Sonia S. Hassan. (2008) Twin-to-twin transfusion syndrome: an antiangiogenic state?. American Journal of Obstetrics and Gynecology 198:4, 382.e1-382.e8
CrossRef362
Anne M. Lynch, James R. Murphy, Tim Byers, Ronald S. Gibbs, Margaret C. Neville, Patricia C. Giclas, Jane E. Salmon, V. Michael Holers. (2008) Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. American Journal of Obstetrics and Gynecology 198:4, 385.e1-385.e9
CrossRef363
Virginia D Winn, Kristy Red-Horse, Susan J Fisher. 2008. Differentiation of the invasive cytotrophoblast lineage in normal pregnancy and in preeclampsia. , 454-465.
CrossRef364
Charles J. Lockwood, Graciela Krikun, Rebeca Caze, Mizanur Rahman, Lynn F. Buchwalder, Frederick Schatz. (2008) Decidual Cell-expressed Tissue Factor in Human Pregnancy and Its Involvement in Hemostasis and Preeclampsia-related Angiogenesis. Annals of the New York Academy of Sciences 1127:1, 67-72
CrossRef365
Makrina D. Savvidou, Qingzhong Xiao, Christine Kaihura, James M. Anderson, Kypros H. Nicolaides. (2008) Maternal circulating endothelial progenitor cells in normal singleton and twin pregnancy. American Journal of Obstetrics and Gynecology 198:4, 414.e1-414.e5
CrossRef366
Nadia Berkane, Alexandre Hertig, Eric Rondeau, Serge Uzan. (2008) Hypertensive disorders of pregnancy: future perspectives. A French point of view. Current Opinion in Obstetrics and Gynecology 20:2, 107-109
CrossRef367
Eremina, Vera, Jefferson, J. Ashley, Kowalewska, Jolanta, Hochster, Howard, Haas, Mark, Weisstuch, Joseph, Richardson, Catherine, Kopp, Jeffrey B., Kabir, M. Golam, Backx, Peter H., Gerber, Hans-Peter, Ferrara, Napoleone, Barisoni, Laura, Alpers, Charles E., Quaggin, Susan E., . (2008) VEGF Inhibition and Renal Thrombotic Microangiopathy. New England Journal of Medicine 358:11, 1129-1136
Full Text368
Magdalena Grundmann, Alexander Woywodt, Torsten Kirsch, Bettina Hollwitz, Katrin Oehler, Uta Erdbruegger, Hermann Haller, Marion Haubitz. (2008) Circulating endothelial cells: a marker of vascular damage in patients with preeclampsia. American Journal of Obstetrics and Gynecology 198:3, 317.e1-317.e5
CrossRef369
F. Crispi, E. Llurba, C. Domínguez, P. Martín-Gallán, L. Cabero, E. Gratacós. (2008) Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound in Obstetrics and Gynecology 31:3, 303-309
CrossRef370
Nicola J Robinson, Mark Wareing, Nicola K Hudson, Richard T Blankley, Philip N Baker, John D Aplin, Ian P Crocker. (2008) Oxygen and the liberation of placental factors responsible for vascular compromise. Laboratory Investigation 88:3, 293-305
CrossRef371
Carl A. Nath, Cande V. Ananth, Celeste DeMarco, Anthony M. Vintzileos. (2008) Low birthweight in relation to placental abruption and maternal thrombophilia status. American Journal of Obstetrics and Gynecology 198:3, 293.e1-293.e5
CrossRef372
Bálint Nagy, Hakan Savli, Attila Molvarec, Tibor Várkonyi, Barbara Rigó, Petronella Hupuczi, János Rigó. (2008) Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real-time PCR and melting curve analyses. Clinica Chimica Acta 389:1-2, 126-131
CrossRef373
Peter Dijke, Marie-José Goumans, Evangelia Pardali. (2008) Endoglin in angiogenesis and vascular diseases. Angiogenesis 11:1, 79-89
CrossRef374
IRA M BERNSTEIN, MARILYN J CIPOLLA. (2008) HAEMODYNAMIC CONTRIBUTIONS TO THE PATHOGENESIS OF PREECLAMPSIA AND ECLAMPSIA. Fetal and Maternal Medicine Review 19:01,
CrossRef375
Jane WOOLCOCK, Annemarie HENNESSY, Bei XU, Charlene THORNTON, Jane TOOHER, Angela MAKRIS, Robert OGLE. (2008) Soluble Flt-1 as a diagnostic marker of pre-eclampsia. The Australian and New Zealand Journal of Obstetrics and Gynaecology 48:1, 64-70
CrossRef376
Sharon E. Maynard, Tiffany A. Moore Simas, Matthew J. Solitro, Abraham Rajan, Sybil Crawford, Peter Soderland, Bruce A. Meyer. (2008) Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. American Journal of Obstetrics and Gynecology 198:2, 200.e1-200.e7
CrossRef377
G. Maalouf, E. Mitry, A. Lacout, A. Lièvre, P. Rougier. (2008) Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. Journal of Neurology 255:2, 295-296
CrossRef378
Holger Stepan, Annegret Geipel, Friederike Schwarz, Thomas Krämer, Niels Wessel, Renaldo Faber. (2008) Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. American Journal of Obstetrics and Gynecology 198:2, 175.e1-175.e6
CrossRef379
Sharon Maynard, Franklin H. Epstein, S. Ananth Karumanchi. (2008) Preeclampsia and Angiogenic Imbalance. Annual Review of Medicine 59:1, 61-78
CrossRef380
Hideki NAKATSUKASA, Hisashi MASUYAMA, Norio TAKAMOTO, Yuji HIRAMATSU. (2008) Circulating Leptin and Angiogenic Factors in Preeclampsia Patients. Endocrine Journal 55:3, 565-573
CrossRef381
Walter P. Mutter, S. Ananth Karumanchi. (2008) Molecular mechanisms of preeclampsia. Microvascular Research 75:1, 1-8
CrossRef382
Cees BM Oudejans. (2008) Non-coding RNA and DNA as epigenetic biomarkers for pre-eclampsia. Expert Opinion on Medical Diagnostics 2:1, 81-89
CrossRef383
Sabine Mütze, Sabine Rudnik-Schöneborn, Klaus Zerres, Werner Rath. (2008) Genes and the preeclampsia syndrome. Journal of Perinatal Medicine 36:1, 38-58
CrossRef384
Chikako HIRASHIMA, Akihide OHKUCHI, Shigeki MATSUBARA, Hirotada SUZUKI, Kayo TAKAHASHI, Rie USUI, Mitsuaki SUZUKI. (2008) Alteration of Serum Soluble Endoglin Levels after the Onset of Preeclampsia Is More Pronounced in Women with Early-Onset. Hypertension Research 31:8, 1541-1548
CrossRef385
Debra Goldman-Wohl, Simcha Yagel. (2008) NK cells and pre-eclampsia. Reproductive BioMedicine Online 16:2, 227-231
CrossRef386
Ivan D. Maya. (2008) Hypertension and Proteinuria in a 17-Year-Old at 19 Weeks’ Gestation. American Journal of Kidney Diseases 51:1, 155-159
CrossRef387
Yoav Yinon, Ori Nevo, Jing Xu, Ariel Many, Alessandro Rolfo, Tullia Todros, Martin Post, Isabella Caniggia. (2008) Severe Intrauterine Growth Restriction Pregnancies Have Increased Placental Endoglin Levels. The American Journal of Pathology 172:1, 77-85
CrossRef388
Nora Franceschini, Chunfang Qiu, David A. Barrow, Michelle A. Williams. (2008) Cystatin C and Preeclampsia: A Case Control Study. Renal Failure 30:1, 89-95
CrossRef389
Mounira Habli, Baha M. Sibai. 2008. Hypertension in Pregnancy. , 479-485.
CrossRef390
Yuditiya Purwosunu, Akihiko Sekizawa, Antonio Farina, Noroyono Wibowo, Keiko Koide, Shiho Okazaki, Masamitsu Nakamura, Takashi Okai. (2008) Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors. American Journal of Obstetrics and Gynecology 198:1, 124.e1-124.e7
CrossRef391
Paul D. Speer, Robert W. Powers, Michael P. Frank, Gail Harger, Nina Markovic, James M. Roberts. (2008) Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. American Journal of Obstetrics and Gynecology 198:1, 112.e1-112.e7
CrossRef392
Minna Tikkanen, Ulf-Håkan Stenman, Mika Nuutila, Jorma Paavonen, Vilho Hiilesmaa, Olavi Ylikorkala. (2007) Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption. Prenatal Diagnosis 27:12, 1143-1146
CrossRef393
Keiko Shibuya, Ritsuko Komaki, Tomoaki Shintani, Satoshi Itasaka, Anderson Ryan, Juliane M. Jürgensmeier, Luka Milas, Kian Ang, Roy S. Herbst, Michael S. O'Reilly. (2007) Targeted Therapy Against VEGFR and EGFR With ZD6474 Enhances the Therapeutic Efficacy of Irradiation in an Orthotopic Model of Human Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 69:5, 1534-1543
CrossRef394
Hernan D. Kopcow, S. Ananth Karumanchi. (2007) Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. Journal of Reproductive Immunology 76:1-2, 23-29
CrossRef395
Babbette D. LaMarca, Michael J. Ryan, Jeffrey S. Gilbert, Sydney R. Murphy, Joey P. Granger. (2007) Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Current Hypertension Reports 9:6, 480-485
CrossRef396
Joaquin Santolaya-Forgas, Samuel Edwin, Katie Zeiter, Adam Pitt, Beth Pineles, Adi L. Tarca, Jimmy Espinoza, Juan Pedro Kusanovic, Offer Erez, Roman Wolf, Roberto Romero. (2007) The timed-pregnant baboon animal model can be used for determining the role of soluble vascular endothelial growth factor receptors 1 and 2 during development. Journal of Medical Primatology 36:6, 370-374
CrossRef397
Luigi Cobellis, Annunziata Mastrogiacomo, Elisabetta Federico, Maria Teresa Schettino, Maria Falco, Lucrezia Manente, Gabriele Coppola, Marco Torella, Nicola Colacurci, Antonio Luca. (2007) Distribution of Notch protein members in normal and preeclampsia-complicated placentas. Cell and Tissue Research 330:3, 527-534
CrossRef398
Irina Banzola, Antonio Farina, Manuela Concu, Akihiko Sekizawa, Yuditiya Purwosunu, Isabella Strada, Diego Arcelli, Giuliana Simonazzi, Elisabetta Caramelli, Nicola Rizzo. (2007) Performance of a panel of maternal serum markers in predicting preeclampsia at 11–15 weeks' gestation. Prenatal Diagnosis 27:11, 1005-1010
CrossRef399
Shiho Okazaki, Akihiko Sekizawa, Yuditiya Purwosunu, Antonio Farina, Noroyono Wibowo, Takashi Okai. (2007) Placenta-Derived, Cellular Messenger RNA Expression in the Maternal Blood of Preeclamptic Women. Obstetrics & Gynecology 110:5, 1130-1136
CrossRef400
Markus Schmidt, Canan Dogan, Cahid Birdir, Rainer Callies, Ulrich Kuhn, Alexandra Gellhaus, Alfred Janetzko, Rainer Kimmig, Sabine Kasimir-Bauer. (2007) Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor. Clinical Chemistry and Laboratory Medicine 45:11, 1504-1510
CrossRef401
P. Hoffmann, J.-J. Feige, N. Alfaidy. (2007) Placental Expression of EG-VEGF and its Receptors PKR1 (Prokineticin Receptor-1) and PKR2 Throughout Mouse Gestation. Placenta 28:10, 1049-1058
CrossRef402
Fangxian Lu, Egle Bytautiene, Esther Tamayo, Phyllis Gamble, Garland D. Anderson, Gary D.V. Hankins, Monica Longo, George R. Saade. (2007) Gender-specific effect of overexpression of sFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in life. American Journal of Obstetrics and Gynecology 197:4, 418.e1-418.e5
CrossRef403
Carmen González, Adalberto Parra, Jorge Ramírez-Peredo, Celina García, José Carlos Rivera, Yazmín Macotela, Jorge Aranda, Maria Lemini, José Arias, Francisco Ibargüengoitia, Gonzalo Martínez de la Escalera, Carmen Clapp. (2007) Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Laboratory Investigation 87:10, 1009-1017
CrossRef404
Steven J Wagner, Vesna D Garovic. (2007) Method of diagnosing pre-eclampsia. Expert Opinion on Medical Diagnostics 1:2, 299-302
CrossRef405
JANE L HOLT, GEORGE J MANGOS, MARK A BROWN. (2007) Measuring protein excretion in pregnancy. Nephrology 12:5, 425-430
CrossRef406
W. Plasencia, N. Maiz, S. Bonino, C. Kaihura, K. H. Nicolaides. (2007) Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound in Obstetrics and Gynecology 30:5, 742-749
CrossRef407
Ramkrishna Mehendale, Judith Hibbard, Asgerally Fazleabas, Richard Leach. (2007) Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. American Journal of Obstetrics and Gynecology 197:4, 363.e1-363.e5
CrossRef408
Tereza Cindrova-Davies, Hong-Wa Yung, Jemma Johns, Olivera Spasic-Boskovic, Svitlana Korolchuk, Eric Jauniaux, Graham J. Burton, D. Stephen Charnock-Jones. (2007) Oxidative Stress, Gene Expression, and Protein Changes Induced in the Human Placenta during Labor. The American Journal of Pathology 171:4, 1168-1179
CrossRef409
Anna Kanerva, Mari Raki, Akseli Hemminki. (2007) Gene therapy of gynaecological diseases. Expert Opinion on Biological Therapy 7:9, 1347-1361
CrossRef410
K Pryor-Koishi, H Nishizawa, T Kato, H Kogo, T Murakami, K Tsuchida, H Kurahashi, Y Udagawa. (2007) Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology 114:9, 1128-1137
CrossRef411
Tiffany A. Moore Simas, Sybil L. Crawford, Matthew J. Solitro, Sara C. Frost, Bruce A. Meyer, Sharon E. Maynard. (2007) Angiogenic factors for the prediction of preeclampsia in high-risk women. American Journal of Obstetrics and Gynecology 197:3, 244.e1-244.e8
CrossRef412
Katie M. Groom, Katrina K. Poppe, Robyn A. North, Lesley M.E. McCowan. (2007) Small-for-gestational-age infants classified by customized or population birthweight centiles: impact of gestational age at delivery. American Journal of Obstetrics and Gynecology 197:3, 239.e1-239.e5
CrossRef413
Jae-Yoon Shim, Jong Kwan Jun, Bok-Kyung Jung, Sung Hoon Kim, Hye-Sung Won, Pil Ryang Lee, Ahm Kim. (2007) Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women. American Journal of Obstetrics and Gynecology 197:3, 271.e1-271.e4
CrossRef414
Mike S Rogers. (2007) Prediction of pre-eclampsia in early pregnancy. Women's Health 3:5, 571-582
CrossRef415
Arindel S.R. Maharaj, Patricia A. D'Amore. (2007) Roles for VEGF in the adult. Microvascular Research 74:2-3, 100-113
CrossRef416
Hassane Izzedine, Olivier Rixe, Bertrand Billemont, Alain Baumelou, Gilbert Deray. (2007) Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension. American Journal of Kidney Diseases 50:2, 203-218
CrossRef417
E. Ramsey Unal, Christopher J. Robinson, Donna D. Johnson, Eugene Y. Chang. (2007) Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. American Journal of Obstetrics and Gynecology 197:2, 211.e1-211.e4
CrossRef418
H.H. Kay, S. Zhu, S. Tsoi. (2007) Hypoxia and Lactate Production in Trophoblast Cells. Placenta 28:8-9, 854-860
CrossRef419
Christopher J. Robinson, Donna D. Johnson. (2007) Soluble endoglin as a second-trimester marker for preeclampsia. American Journal of Obstetrics and Gynecology 197:2, 174.e1-174.e5
CrossRef420
Anne Cathrine Staff, Kristin Braekke, Guro M. Johnsen, S. Ananth Karumanchi, Nina Kittelsen Harsem. (2007) Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. American Journal of Obstetrics and Gynecology 197:2, 176.e1-176.e6
CrossRef421
Akira Mende, Hajime Takano, Yasushi Kodama, Takamitsu Nakamura, Ken Umetani, Daisuke Fujioka, Yukio Saito, Tsuyoshi Kobayashi, Ken-ichi Kawabata, Jyun-ei Obata, Yoshinobu Kitta, Kiyotaka Kugiyama. (2007) Relation between transcardiac gradient of VEGF and coronary flow response in humans. International Journal of Cardiology 119:2, 156-162
CrossRef422
Baha M. Sibai. (2007) Biomarker for hypertension-preeclampsia: are we close yet?. American Journal of Obstetrics and Gynecology 197:1, 1-2
CrossRef423
Saira Salahuddin, Young Lee, Mary Vadnais, Benjamin P. Sachs, S. Ananth Karumanchi, Kee-Hak Lim. (2007) Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. American Journal of Obstetrics and Gynecology 197:1, 28.e1-28.e6
CrossRef424
Ilana Chafetz, Ido Kuhnreich, Marei Sammar, Yossi Tal, Yair Gibor, Hamutal Meiri, Howard Cuckle, Myles Wolf. (2007) First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. American Journal of Obstetrics and Gynecology 197:1, 35.e1-35.e7
CrossRef425
Gordon C. S. Smith, Jennifer A. Crossley, David A. Aitken, Nicola Jenkins, Fiona Lyall, Alan D. Cameron, J Michael Connor, Richard Dobbie. (2007) Circulating Angiogenic Factors in Early Pregnancy and the Risk of Preeclampsia, Intrauterine Growth Restriction, Spontaneous Preterm Birth, and Stillbirth. Obstetrics & Gynecology 109:6, 1316-1324
CrossRef426
Anna-Karin Wikström, Anders Larsson, Ulf J. Eriksson, Peppi Nash, Solveig Nordén-Lindeberg, Matts Olovsson. (2007) Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 in Early-Onset and Late-Onset Preeclampsia. Obstetrics & Gynecology 109:6, 1368-1374
CrossRef427
Gary A. Dildy, Michael A. Belfort, John C. Smulian. (2007) Preeclampsia Recurrence and Prevention. Seminars in Perinatology 31:3, 135-141
CrossRef428
Robert A Dyer, Jenna L Piercy, Anthony R Reed. (2007) The role of the anaesthetist in the management of the pre-eclamptic patient. Current Opinion in Anaesthesiology 20:3, 168-174
CrossRef429
Jianhong Zhang, Zhigang Tian. (2007) UNK cells: their role in tissue re-modelling and preeclampsia. Seminars in Immunopathology 29:2, 123-133
CrossRef430
A Makris, C Thornton, J Thompson, S Thomson, R Martin, R Ogle, R Waugh, P McKenzie, P Kirwan, A Hennessy. (2007) Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney International 71:10, 977-984
CrossRef431
Dinesh M Shah. (2007) Preeclampsia: new insights. Current Opinion in Nephrology and Hypertension 16:3, 213-220
CrossRef432
S A Karumanchi, F H Epstein. (2007) Placental ischemia and soluble fms-like tyrosine kinase 1: Cause or consequence of preeclampsia?. Kidney International 71:10, 959-961
CrossRef433
H. Nishizawa, K. Pryor-Koishi, T. Kato, H. Kowa, H. Kurahashi, Y. Udagawa. (2007) Microarray Analysis of Differentially Expressed Fetal Genes in Placental Tissue Derived from Early and Late Onset Severe Pre-eclampsia. Placenta 28:5-6, 487-497
CrossRef434
Jimmy Espinoza, Roberto Romero, Jyh Kae Nien, Ricardo Gomez, Juan Pedro Kusanovic, Luis F. Gonçalves, Luis Medina, Sam Edwin, Sonia Hassan, Mario Carstens, Rogelio Gonzalez. (2007) Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. American Journal of Obstetrics and Gynecology 196:4, 326.e1-326.e13
CrossRef435
S. Ananth Karumanchi, Marshall D. Lindheimer. (2007) Preeclampsia and the kidney: footprints in the urine. American Journal of Obstetrics and Gynecology 196:4, 287-288
CrossRef436
KM Groom, RA North, KK Poppe, L Sadler, LME McCowan. (2007) The association between customised small for gestational age infants and pre-eclampsia or gestational hypertension varies with gestation at delivery. BJOG: An International Journal of Obstetrics & Gynaecology 114:4, 478-484
CrossRef437
Charles J. Lockwood, Paolo Toti, Felice Arcuri, Errol Norwitz, Edmund F. Funai, Se-Te J. Huang, Lynn F. Buchwalder, Graciela Krikun, Frederick Schatz. (2007) Thrombin Regulates Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) Expression in First Trimester Decidua. The American Journal of Pathology 170:4, 1398-1405
CrossRef438
Debbra A. Keegan, Lewis C. Krey, Hung-Chi Chang, Nicole Noyes. (2007) Increased risk of pregnancy-induced hypertension in young recipients of donated oocytes. Fertility and Sterility 87:4, 776-781
CrossRef439
Fangxian Lu, Monica Longo, Esther Tamayo, William Maner, Ayman Al-Hendy, Garland D. Anderson, Gary D.V. Hankins, George R. Saade. (2007) The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. American Journal of Obstetrics and Gynecology 196:4, 396.e1-396.e7
CrossRef440
Vesna D. Garovic, Steven J. Wagner, Stephen T. Turner, David W. Rosenthal, William J. Watson, Brian C. Brost, Carl H. Rose, Larisa Gavrilova, Paula Craigo, Kent R. Bailey, Johannes Achenbach, Mario Schiffer, Joseph P. Grande. (2007) Urinary podocyte excretion as a marker for preeclampsia. American Journal of Obstetrics and Gynecology 196:4, 320.e1-320.e7
CrossRef441
D. Schlembach, W. Wallner, R. Sengenberger, E. Stiegler, M. Mörtl, M. W. Beckmann, U. Lang. (2007) Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound in Obstetrics and Gynecology 29:4, 407-413
CrossRef442
Roshan Fernando. (2007) Gerard W. Ostheimer ???What???s New in Obstetric Anesthesia??? Lecture. Anesthesiology 106:3, 615-621
CrossRef443
Anita N. Haggstrom, Beth A. Drolet, Eulalia Baselga, Sarah L. Chamlin, Maria C. Garzon, Kimberly A. Horii, Anne W. Lucky, Anthony J. Mancini, Denise W. Metry, Brandon Newell, Amy J. Nopper, Ilona J. Frieden. (2007) Prospective Study of Infantile Hemangiomas: Demographic, Prenatal, and Perinatal Characteristics. The Journal of Pediatrics 150:3, 291-294
CrossRef444
Tatsuro Yamaguchi, Hiroko Bando, Takeo Mori, Keiichi Takahashi, Hiroshi Matsumoto, Michiya Yasutome, Herbert A. Weich, Masakazu Toi. (2007) Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis. Cancer Science 98:3, 405-410
CrossRef445
Lars J. Vatten, Anne Eskild, Tom I.L. Nilsen, Stig Jeansson, Pål A. Jenum, Anne Cathrine Staff. (2007) Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. American Journal of Obstetrics and Gynecology 196:3, 239.e1-239.e6
CrossRef446
Kevin Spencer, Nicholas J. Cowans, Ilana Chefetz, Joseph Tal, Ido Kuhnreich, Hamutal Meiri. (2007) Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenatal Diagnosis 27:3, 258-263
CrossRef447
Sarosh Rana, Shivalingappa Venkatesha, Monique DePaepe, Edward K. Chien, Michael Paglia, S Ananth Karumanchi. (2007) Cytomegalovirus-Induced Mirror Syndrome Associated With Elevated Levels of Circulating Antiangiogenic Factors. Obstetrics & Gynecology 109:Supplement, 549-552
CrossRef448
Yuri Takemura, Yutaka Osuga, Kaori Koga, Toshiki Tajima, Yasushi Hirota, Tetsuya Hirata, Chieko Morimoto, Miyuki Harada, Tetsu Yano, Yuji Taketani. (2007) Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia. Journal of Reproductive Immunology 73:1, 60-65
CrossRef449
K. Spencer, N. J. Cowans, I. Chefetz, J. Tal, H. Meiri. (2007) First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound in Obstetrics and Gynecology 29:2, 128-134
CrossRef450
Vera Eremina, Hans J. Baelde, Susan E. Quaggin. (2007) Role of the VEGF-A Signaling Pathway in the Glomerulus: Evidence for Crosstalk between Components of the Glomerular Filtration Barrier. Nephron Physiology 106:2, p32-p37
CrossRef451
Mariana Widmer, José Villar, Ariela Benigni, Agustin Conde-Agudelo, S Ananth Karumanchi, Marshall Lindheimer. (2007) Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors. Obstetrics & Gynecology 109:1, 168-180
CrossRef452
Suzanne Baumwell, S. Ananth Karumanchi. (2007) Pre-Eclampsia: Clinical Manifestations and Molecular Mechanisms. Nephron Clinical Practice 106:2, c72-c81
CrossRef453
V. Prasad. (2007) Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. Yearbook of Medicine 2007, 190-191
CrossRef454
Akihide OHKUCHI, Chikako HIRASHIMA, Shigeki MATSUBARA, Hirotada SUZUKI, Kayo TAKAHASHI, Fujimi ARAI, Takashi WATANABE, Kazuomi KARIO, Mitsuaki SUZUKI. (2007) Alterations in Placental Growth Factor Levels before and after the Onset of Preeclampsia Are More Pronounced in Women with Early Onset Severe Preeclampsia. Hypertension Research 30:2, 151-159
CrossRef455
Eun Sung Lee, Min-Jeong Oh, Jae Won Jung, Ji-Eun Lim, Hyun-Joo Seol, Kyung-Ju Lee, Hai-Joong Kim. (2007) The Levels of Circulating Vascular Endothelial Growth Factor and Soluble Flt-1 in Pregnancies Complicated by Preeclampsia. Journal of Korean Medical Science 22:1, 94
CrossRef456
Sarosh Rana, Marshall D Lindheimer, Ananth Karumanchi. (2007) Angiogenic proteins as markers for predicting preeclampsia. Expert Review of Obstetrics & Gynecology 2:1, 61-65
CrossRef457
Shin-Young Kim, Hyun-Mee Ryu, Jae-Hyug Yang, Moon-Young Kim, Jung-Yeol Han, Joo-Oh Kim, Jin-Hoon Chung, So-Yeon Park, Moon-Hee Lee, Do-Jin Kim. (2007) Increased sFlt-1 to PlGF Ratio in Women Who Subsequently Develop Preeclampsia. Journal of Korean Medical Science 22:5, 873
CrossRef458
Ja-Young Kwon, Yong-Son Maeng, Young-Guen Kwon, Young-Han Kim, Moung-Hwa Kang, Yong-Won Park. (2007) Decreased Endothelial Progenitor Cells in Umbilical Cord Blood in Severe Preeclampsia. Gynecologic and Obstetric Investigation 64:2, 103-108
CrossRef459
Mert Ozan Bahtiyar, Catalin Buhimschi, Viswanathan Ravishankar, Joshua Copel, Errol Norwitz, Svena Julien, Seth Guller, Irina A. Buhimschi. (2007) Contrasting effects of chronic hypoxia and nitric oxide synthase inhibition on circulating angiogenic factors in a rat model of growth restriction. American Journal of Obstetrics and Gynecology 196:1, 72.e1-72.e6
CrossRef460
Masaubmi Shibuya. (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9:4, 225-230
CrossRef461
Makrina D. Savvidou, Christina K. Yu, Lisa C. Harland, Aroon D. Hingorani, Kypros H. Nicolaides. (2006) Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. American Journal of Obstetrics and Gynecology 195:6, 1668-1673
CrossRef462
Naoko Suwaki, Hisashi Masuyama, Hideki Nakatsukasa, Akio Masumoto, Yumi Sumida, Norio Takamoto, Yuji Hiramatrsu. (2006) Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. American Journal of Obstetrics and Gynecology 195:6, 1687-1692
CrossRef463
Benjamin D. Hamar, Irina A. Buhimschi, Anna K. Sfakianaki, Christian M. Pettker, Lissa K. Magloire, Edmund F. Funai, Joshua A. Copel, Catalin S. Buhimschi. (2006) Serum and urine inhibin A but not free activin A are endocrine biomarkers of severe pre-eclampsia. American Journal of Obstetrics and Gynecology 195:6, 1636-1645
CrossRef464
Aris T Papageorghiou, Stuart Campbell. (2006) First trimester screening for preeclampsia. Current Opinion in Obstetrics and Gynecology 18:6, 594-600
CrossRef465
Balamurali K. Ambati, Miho Nozaki, Nirbhai Singh, Atsunobu Takeda, Pooja D. Jani, Tushar Suthar, Romulo J. C. Albuquerque, Elizabeth Richter, Eiji Sakurai, Michael T. Newcomb, Mark E. Kleinman, Ruth B. Caldwell, Qing Lin, Yuichiro Ogura, Angela Orecchia, Don A. Samuelson, Dalen W. Agnew, Judy St. Leger, W. Richard Green, Parameshwar J. Mahasreshti, David T. Curiel, Donna Kwan, Helene Marsh, Sakae Ikeda, Lucy J. Leiper, J. Martin Collinson, Sasha Bogdanovich, Tejvir S. Khurana, Masabumi Shibuya, Megan E. Baldwin, Napoleone Ferrara, Hans-Peter Gerber, Sandro De Falco, Jassir Witta, Judit Z. Baffi, Brian J. Raisler, Jayakrishna Ambati. (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:7114, 993-997
CrossRef466
Scott M Nelson, Ian A Greer. (2006) Hypertensive disorders of pregnancy: preventative-, immediate- and long-term management. Expert Review of Pharmacoeconomics & Outcomes Research 6:5, 541-554
CrossRef467
Masabumi Shibuya. (2006) Differential Roles of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Angiogenesis. Journal of Biochemistry and molecular biology 39:5, 469-478
CrossRef468
Lindheimer, Marshall D., Umans, Jason G., . (2006) Explaining and Predicting Preeclampsia. New England Journal of Medicine 355:10, 1056-1058
Full Text469
Levine, Richard J., Lam, Chun, Qian, Cong, Yu, Kai F., Maynard, Sharon E., Sachs, Benjamin P., Sibai, Baha M., Epstein, Franklin H., Romero, Roberto, Thadhani, Ravi, Karumanchi, S. Ananth, . (2006) Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. New England Journal of Medicine 355:10, 992-1005
Full Text470
Kjersti M. Aagaard-Tillery, Gregory J. Stoddard, Calla Holmgren, D. Yvette Lacoursiere, Alison Fraser, Geraldine P. Mineau, Michael W. Varner. (2006) Preeclampsia and subsequent risk of cancer in Utah. American Journal of Obstetrics and Gynecology 195:3, 691-699
CrossRef471
Toshiyuki Imasawa, Tetsuji Nishiwaki, Motonobu Nishimura, Nobuaki Shikama, Ryutaro Matsumura, Masaaki Nagai, Akiko Soyama, Kentaro Koike, Hiroshi Kitamura, Kensuke Joh. (2006) A Case of “Pure” Preeclampsia With Nephrotic Syndrome Before 15 Weeks of Gestation in a Patient Whose Renal Biopsy Showed Glomerular Capillary Endotheliosis. American Journal of Kidney Diseases 48:3, 495-501
CrossRef472
Caroline Signore, James L. Mills, Cong Qian, Kai Yu, Chun Lam, Franklin H. Epstein, S Ananth Karumanchi, Richard J. Levine. (2006) Circulating Angiogenic Factors and Placental Abruption. Obstetrics & Gynecology 108:2, 338-344
CrossRef473
Keiichi Matsubara, Emiko Abe, Yuko Matsubara, Kenji Kameda, Masaharu Ito. (2006) Circulating Endothelial Progenitor Cells During Normal Pregnancy and Pre-Eclampsia. American Journal of Reproductive Immunology 56:2, 79-85
CrossRef474
Lin Wang, Yan Feng, Yan Zhang, Huanyu Zhou, Shanqun Jiang, Tianhua Niu, Lee-Jen Wei, Xin Xu, Xiping Xu, Xiaobin Wang. (2006) Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. American Journal of Obstetrics and Gynecology 195:1, 162-171
CrossRef475
Fàtima Crispi, Carmen Domínguez, Elisa Llurba, Pilar Martín-Gallán, Luís Cabero, Eduard Gratacós. (2006) Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. American Journal of Obstetrics and Gynecology 195:1, 201-207
CrossRef476
Betty Y Y Tam, Kevin Wei, John S Rudge, Jana Hoffman, Joceyln Holash, Sang-ki Park, Jenny Yuan, Colleen Hefner, Cecile Chartier, Jeng-Shin Lee, Shelly Jiang, Nihar R Niyak, Frans A Kuypers, Lisa Ma, Uma Sundram, Grace Wu, Joseph A Garcia, Stanley L Schrier, Jacquelyn J Maher, Randall S Johnson, George D Yancopoulos, Richard C Mulligan, Calvin J Kuo. (2006) VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nature Medicine 12:7, 793-800
CrossRef477
Jennifer Hirshfeld-Cytron, Chun Lam, S Ananth Karumanchi, Marshall Lindheimer. (2006) Late Postpartum Eclampsia: Examples and Review. Obstetrical & Gynecological Survey 61:7, 471-480
CrossRef478
M S Goligorsky, T Rabelink. (2006) Meeting report: ISN forefronts in nephrology on endothelial biology and renal disease: from bench to prevention. Kidney International 70:2, 258-264
CrossRef479
Roberta B. Ness, Baha M. Sibai. (2006) Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. American Journal of Obstetrics and Gynecology 195:1, 40-49
CrossRef480
Christopher J. Robinson, Donna D. Johnson, Eugene Y. Chang, D. Michael Armstrong, Wei Wang. (2006) Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. American Journal of Obstetrics and Gynecology 195:1, 255-259
CrossRef481
Shivalingappa Venkatesha, Mourad Toporsian, Chun Lam, Jun-ichi Hanai, Tadanori Mammoto, Yeon M Kim, Yuval Bdolah, Kee-Hak Lim, Hai-Tao Yuan, Towia A Libermann, Isaac E Stillman, Drucilla Roberts, Patricia A D'Amore, Franklin H Epstein, Frank W Sellke, Roberto Romero, Vikas P Sukhatme, Michelle Letarte, S Ananth Karumanchi. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine 12:6, 642-649
CrossRef482
Gülsan Türköz Sucak, Kadir Acar, Ayhan Sucak, Serafettin Kirazl, Rauf Haznedar. (2006) Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia. Blood Coagulation & Fibrinolysis 17:5, 347-352
CrossRef483
Sinuhe Hahn, Anurag Kumar Gupta, Carolyn Troeger, Corinne Rusterholz, Wolfgang Holzgreve. (2006) Disturbances in placental immunology: ready for therapeutic interventions?. Springer Seminars in Immunopathology 27:4, 477-493
CrossRef484
Latisha Love-Gregory, Ann M. Gronowski. (2006) Assessing the Pregnant Patient: A Review of New Potential Screening Tests. Laboratory Medicine 37:6, 371-374
CrossRef485
Paul C. Welch, Kofi S. Amankwah, Patience Miller, Mary E. McAsey, Donald S. Torry. (2006) Correlations of placental perfusion and PlGF protein expression in early human pregnancy. American Journal of Obstetrics and Gynecology 194:6, 1625-1629
CrossRef486
S Ghaem-Maghami, H Cook, A Bird, D Williams. (2006) Case report: High myopia and pre-eclampsia: a blinding combination. BJOG: An International Journal of Obstetrics & Gynaecology 113:5, 608-609
CrossRef487
Anna-Karin Olsson, Anna Dimberg, Johan Kreuger, Lena Claesson-Welsh. (2006) VEGF receptor signalling — in control of vascular function. Nature Reviews Molecular Cell Biology 7:5, 359-371
CrossRef488
Catalin S. Buhimschi, Lissa Magloire, Edmund Funai, Errol R. Norwitz, Edward Kuczynski, Ryan Martin, Susan Richman, Seth Guller, Charles J. Lockwood, Irina A. Buhimschi. (2006) Fractional Excretion of Angiogenic Factors in Women With Severe Preeclampsia. Obstetrics & Gynecology 107:5, 1103-1113
CrossRef489
S McGrath-Morrow, C Cho, R Molls, M Burne-Taney, M Haas, D J Hicklin, R Tuder, H Rabb. (2006) VEGF receptor 2 blockade leads to renal cyst formation in mice. Kidney International 69:10, 1741-1748
CrossRef490
Stepan, Holger, Faber, Renaldo, . (2006) Elevated sFlt1 Level and Preeclampsia with Parvovirus-Induced Hydrops. New England Journal of Medicine 354:17, 1857-1858
Full Text491
Richard J. Levine, Cong Qian, Sharon E. Maynard, Kai F. Yu, Franklin H. Epstein, S. Ananth Karumanchi. (2006) Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. American Journal of Obstetrics and Gynecology 194:4, 1034-1041
CrossRef492
Peilin Zhang, Matrina Schmidt, Linda Cook. (2006) Maternal vasculopathy and histologic diagnosis of preeclampsia: Poor correlation of histologic changes and clinical manifestation. American Journal of Obstetrics and Gynecology 194:4, 1050-1056
CrossRef493
Brenda A. Bucklin. (2006) Gerard W. Ostheimer ???What???s New in Obstetric Anesthesia??? Lecture. Anesthesiology 104:4, 865-871
CrossRef494
Anna Maria Siega-Riz, Andy F. Olshan, Martha M. Werler, Cynthia Moore, . (2006) Fat intake and the risk of gastroschisis. Birth Defects Research Part A: Clinical and Molecular Teratology 76:4, 241-245
CrossRef495
Hisashi Masuyama, Naoko Suwaki, Hideki Nakatsukasa, Akio Masumoto, Yoko Tateishi, Yuji Hiramatrsu. (2006) Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. American Journal of Obstetrics and Gynecology 194:2, 551-556
CrossRef496
Eva M.L. Smets, Allerdien Visser, Attie T.J.I. Go, John M.G. van Vugt, Cees B.M. Oudejans. (2006) Novel biomarkers in preeclampsia. Clinica Chimica Acta 364:1-2, 22-32
CrossRef497
P K Aggarwal, V Jain, V Sakhuja, S A Karumanchi, V Jha. (2006) Low urinary placental growth factor is a marker of pre-eclampsia. Kidney International 69:3, 621-624
CrossRef498
Shen Hongling, Li Hongyu, Chen Hanping, Guo Yuzhen, Zhang Ming, Xu Xiaoyan, Xiang Wenpei. (2006) Analysis of placental growth factor in placentas of normal pregnant women and women with hypertensive disorders of pregnancy. Journal of Huazhong University of Science and Technology [Medical Sciences] 26:1, 116-119
CrossRef499
Aura G Giurgea, Christian Margeta, Thomas Maca, Abdolreza Rezaie-Majd, Robert A Bucek, Mahmood Manavi, Reza Afarideh, Erich Minar, Mehrdad Baghestanian. (2006) Simvastatin Reduces Serum Level of Vascular Endothelial Growth Factor in Hypercholesterolemic Patients. Journal of Cardiovascular Pharmacology 47:1, 30-36
CrossRef500
S THUNG. (2006) Urinary Placental Growth Factor and Risk of PreeclampsiaLevine RJ, Thadhani R, Qian C, et al (Natl Inst of Child Health and Human Development, Bethesda, Md; Harvard Med School, Boston; Allied Technology Group, Rockville, Md; et al) JAMA 293:77–85, 2005§. Yearbook of Obstetrics, Gynecology and Women's Health 2006, 71-72
CrossRef501
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Williams, Winfred W. Jr., Ecker, Jeffrey L., Thadhani, Ravi I., Rahemtullah, Aliyah, . (2005) Case 38-2005. New England Journal of Medicine 353:24, 2590-2600
Full Text502
Leigh Coultas, Kallayanee Chawengsaksophak, Janet Rossant. (2005) Endothelial cells and VEGF in vascular development. Nature 438:7070, 937-945
CrossRef503
Holger Stepan, Renaldo Faber. (2005) Urinary angiogenic factors in preeclampsia. American Journal of Obstetrics and Gynecology 193:6, 2181-2182
CrossRef504
Kaya Matsubara, Takeshi Nagamatsu, Tomoyuki Fujii, Shiro Kozuma, Yuji Taketani. (2005) Lymphokine-activated killer cells induced from decidual lymphocytes reduce the angiogenic activity of trophoblasts by enhancing the release of soluble fms-like tyrosine kinase-1 from trophoblasts: An implication for the pathophysiology of preeclampsia. Journal of Reproductive Immunology 68:1-2, 27-37
CrossRef505
Aris T Papageorghiou, Nicole Roberts. (2005) Uterine artery Doppler screening for adverse pregnancy outcome. Current Opinion in Obstetrics and Gynecology 17:6, 584-590
CrossRef506
Marina Noris, Norberto Perico, Giuseppe Remuzzi. (2005) Mechanisms of Disease: pre-eclampsia. Nature Clinical Practice Nephrology 1:2, 98-114
CrossRef507
William H. Frishman, Stacy J. Schlocker, Ketti Awad, Nergesh Tejani. (2005) Pathophysiology and Medical Management of Systemic Hypertension in Pregnancy. Cardiology in Review 13:6, 274-284
CrossRef508
Anurag Kumar Gupta, Paul Hasler, Wolfgang Holzgreve, Stefan Gebhardt, Sinuhe Hahn. (2005) Induction of Neutrophil Extracellular DNA Lattices by Placental Microparticles and IL-8 and Their Presence in Preeclampsia. Human Immunology 66:11, 1146-1154
CrossRef509
Stephen P. Emery, Richard J. Levine, Cong Qian, Marian G. Ewell, Lucinda J. England, Kai F. Yu, Patrick M. Catalano, . (2005) Twenty-four-hour urine insulin as a measure of hyperinsulinaemia/insulin resistance before onset of pre-eclampsia and gestational hypertension. BJOG: An International Journal of Obstetrics and Gynaecology 112:11, 1479-1485
CrossRef510
Roberta B. Ness, Carl A. Hubel. (2005) Risk for Coronary Artery Disease and Morbid Preeclampsia: A Commentary. Annals of Epidemiology 15:9, 726-733
CrossRef511
Mauro Parra, Ramón Rodrigo, Pilar Barja, Cleofina Bosco, Virginia Fernández, Hernán Muñoz, Emiliano Soto-Chacón. (2005) Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. American Journal of Obstetrics and Gynecology 193:4, 1486-1491
CrossRef512
Chan-Wook Park, Joong Shin Park, Soon-Sup Shim, Jong Kwan Jun, Bo Hyun Yoon, Roberto Romero. (2005) An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. American Journal of Obstetrics and Gynecology 193:3, 984-989
CrossRef513
Eugene Y. Chang, Ernest Barbosa, M.K. Paintlia, Avtar Singh, Inderjit Singh. (2005) The use of N-acetylcysteine for the prevention of hypertension in the reduced uterine perfusion pressure model for preeclampsia in Sprague-Dawley rats. American Journal of Obstetrics and Gynecology 193:3, 952-956
CrossRef514
Maryann Mugo, Gurushankar Govindarajan, L. Romayne Kurukulasuriya, James R. Sowers, Samy I. McFarlane. (2005) Hypertension in pregnancy. Current Hypertension Reports 7:5, 348-354
CrossRef515
Darcy B. Carr, Meira Epplein, Catherine O. Johnson, Thomas R. Easterling, Cathy W. Critchlow. (2005) A sister's risk: Family history as a predictor of preeclampsia. American Journal of Obstetrics and Gynecology 193:3, 965-972
CrossRef516
Ramón Rodrigo, Mauro Parra, Cleofina Bosco, Virginia Fernández, Pilar Barja, José Guajardo, Rodrigo Messina. (2005) Pathophysiological basis for the prophylaxis of preeclampsia through early supplementation with antioxidant vitamins. Pharmacology & Therapeutics 107:2, 177-197
CrossRef517
Diane C. Bodurka. (2005) What’s New in Gynecology and Obstetrics. Journal of the American College of Surgeons 201:2, 265-274
CrossRef518
Nick A. Bersinger, Ronnaug A. Odegard. (2005) Serum Levels of Macrophage Colony Stimulating, Vascular Endothelial, and Placenta Growth Factor in Relation to Later Clinical Onset of Pre-Eclampsia and a Small-for-Gestational Age Birth. American Journal of Reproductive Immunology 54:2, 77-83
CrossRef519
Myles Wolf, Anand Shah, Chun Lam, Abelardo Martinez, Karen V. Smirnakis, Franklin H. Epstein, Robert N. Taylor, Jeffrey L. Ecker, S. Ananth Karumanchi, Ravi Thadhani. (2005) Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. American Journal of Obstetrics and Gynecology 193:1, 16-22
CrossRef520
Aaron B. Caughey, Naomi E. Stotland, A Eugene Washington, Gabriel J. Escobar. (2005) Maternal Ethnicity, Paternal Ethnicity, and Parental Ethnic Discordance. Obstetrics & Gynecology 106:1, 156-161
CrossRef521
R.W. Powers, J.M. Roberts, K.M. Cooper, M.J. Gallaher, M.P. Frank, G.F. Harger, R.B. Ness. (2005) Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. American Journal of Obstetrics and Gynecology 193:1, 185-191
CrossRef522
X. SALCEDO, J. MEDINA, P. SANZ-CAMENO, L. GARCIA-BUEY, S. MARTIN-VILCHEZ, R. MORENO-OTERO. (2005) Review article: angiogenesis soluble factors as liver disease markers. Alimentary Pharmacology and Therapeutics 22:1, 23-30
CrossRef523
Shang-mian Yie, Robert N. Taylor, Clifford Librach. (2005) Low plasma HLA-G protein concentrations in early gestation indicate the development of preeclampsia later in pregnancy. American Journal of Obstetrics and Gynecology 193:1, 204-208
CrossRef524
Arohan Subramanya, Donald Houghton, Suzanne Watnick. (2005) Steroid-Responsive Idiopathic Glomerular Capillary Endotheliosis: Case Report and Literature Review. American Journal of Kidney Diseases 45:6, 1090-1095
CrossRef525
John M O??Brien, John R Barton. (2005) Controversies With the Diagnosis and Management of HELLP Syndrome. Clinical Obstetrics and Gynecology 48:2, 460-477
CrossRef526
Richard J Levine, S Ananth Karumanchi. (2005) Circulating Angiogenic Factors in Preeclampsia. Clinical Obstetrics and Gynecology 48:2, 372-386
CrossRef527
S. Ananth Karumanchi, Sharon E. Maynard, Isaac E. Stillman, Franklin H. Epstein, Vikas P. Sukhatme. (2005) Preeclampsia: A renal perspective. Kidney International 67:6, 2101-2113
CrossRef528
Nora Franceschini, David A. Savitz, Jay S. Kaufman, John M. Thorp. (2005) Maternal Urine Albumin Excretion and Pregnancy Outcome. American Journal of Kidney Diseases 45:6, 1010-1018
CrossRef529
Reynir Arngrímsson. (2005) Epigenetics of hypertension in pregnancy. Nature Genetics 37:5, 460-461
CrossRef530
SHARON E. MAYNARD, SHIVALINGAPPA VENKATESHA, RAVI THADHANI, S ANANTH KARUMANCHI. (2005) Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia. Pediatric Research 57:5 Part 2, 1R-7R
CrossRef531
Charlotta Dabrosin. (2005) Sex steroid regulation of angiogenesis in breast tissue. Angiogenesis 8:2, 127-136
CrossRef532
Richard Lafayette. (2005) The kidney in preeclampsia. Kidney International 67:3, 1194-1203
CrossRef533
Gerdur A. Arnadottir, Reynir T. Geirsson, Reynir Arngrimsson, Lilja S. Jonsdottir, Orn Olafsson. (2005) Cardiovascular death in women who had hypertension in pregnancy: a case-control study. BJOG: An International Journal of Obstetrics and Gynaecology 112:3, 286-292
CrossRef534
Catalin S. Buhimschi, Errol R. Norwitz, Edmund Funai, Susan Richman, Seth Guller, Charles J. Lockwood, Irina A. Buhimschi. (2005) Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. American Journal of Obstetrics and Gynecology 192:3, 734-741
CrossRef535
TOMAS LENZ, STEFAN GAUER, HERBERT A WEICH, THOMAS HAAK, RAOUL BERGNER, JAN GOSSMANN. (2005) Vascular endothelial growth factor and its soluble receptor, Flt-1, are not correlated to erythropoietin in diabetics with normal or reduced renal function. Nephrology 10:1, 84-89
CrossRef536
Baha Sibai, Gus Dekker, Michael Kupferminc. (2005) Pre-eclampsia. The Lancet 365:9461, 785-799
CrossRef537
Marc E.A. Spaanderman, Christine Willekes, Arnold P.G. Hoeks, Timo H.A. Ekhart, Robert Aardenburg, Dorette A. Courtar, Hugo W.F. van Eijndhoven, Louis L.H. Peeters. (2005) Maternal nonpregnant vascular function correlates with subsequent fetal growth. American Journal of Obstetrics and Gynecology 192:2, 504-512
CrossRef538
H. Li, B. Gu, Y. Zhang, D.F. Lewis, Y. Wang. (2005) Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 26:2-3, 210-217
CrossRef539
H Bando, H A Weich, M Brokelmann, S Horiguchi, N Funata, T Ogawa, M Toi. (2005) Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. British Journal of Cancer
CrossRef540
Zheng Tang, Hongqi Ren, Guang Yang, Huiping Chen, Hong Zhou, Caihong Zeng, Zhihong Liu, Leishi Li. (2005) Significance of Vascular Endothelial Growth Factor Expression in Renal Tissue of Patients with Preeclamptic Nephropathy. American Journal of Nephrology 25:6, 579-585
CrossRef541
Jason K. Baxter, Louis Weinstein. (2004) HELLP Syndrome: The State of the Art. Obstetrical & Gynecological Survey 59:12, 838-845
CrossRef542
Agustin Conde-Agudelo, José Villar, Marshall Lindheimer. (2004) World Health Organization Systematic Review of Screening Tests for Preeclampsia. Obstetrics & Gynecology 104:6, 1367-1391
CrossRef543
Stepan, Holger, Geide, AnneFaber, Renaldo, . (2004) Soluble fms-like Tyrosine Kinase 1. New England Journal of Medicine 351:21, 2241-2242
Full Text544
Geralyn M. Lambert-Messerlian, Jacob A. Canick. (2004) Placenta growth factor levels in second-trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia. Prenatal Diagnosis 24:11, 876-880
CrossRef545
Michael T. McMaster, Yan Zhou, Susan J. Fisher. (2004) Abnormal placentation and the syndrome of preeclampsia. Seminars in Nephrology 24:6, 540-547
CrossRef546
Eduardo Podjarny, Gyorgy Losonczy, Chris Baylis. (2004) Animal models of preeclampsia. Seminars in Nephrology 24:6, 596-606
CrossRef547
Yuval Bdolah, Vikas P. Sukhatme, S. Ananth Karumanchi. (2004) Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. Seminars in Nephrology 24:6, 548-556
CrossRef548
B. Anne Croy, Malcolm G. Baines. (2004) Face-Offs in Reproductive Immunology: The Montreal Forum Meeting Report. American Journal of Reproductive Immunology 52:4, 233-236
CrossRef549
Baha M. Sibai. (2004) Preeclampsia: An inflammatory syndrome?. American Journal of Obstetrics and Gynecology 191:4, 1061-1062
CrossRef550
Kristy Red-Horse, Yan Zhou, Olga Genbacev, Akraporn Prakobphol, Russell Foulk, Michael McMaster, Susan J. Fisher. (2004) Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. Journal of Clinical Investigation 114:6, 744-754
CrossRef551
(2004) Circulating Angiogenic Factors and Preeclampsia. New England Journal of Medicine 350:19, 2003-2004
Full Text552
Solomon, Caren G., Seely, Ellen W., . (2004) Preeclampsia — Searching for the Cause. New England Journal of Medicine 350:7, 641-642
Full Text553
David C. Sane, Lauren Anton, K. Bridget Brosnihan. (2004) Angiogenic growth factors and hypertension. Angiogenesis 7:3, 193-201
CrossRef
- Letters
